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ABSTRACT 
WEICHEN XU: Peptide-Based Biosensors and Light-Activatable Proteins: 
Tools for Studying Cell Signaling and Developing Cancer Diagnosis 
 (Under the direction of David Lawrence) 
Protein kinases play central roles in almost all aspects of normal and abnormal 
cell functions. Therefore, methods that provide sensitive, selective and controllable 
measurement of kinase activity should prove useful for studying cell signaling events. 
Moreover, easy to operate, generalizable strategies are in high demand for disease 
diagnosis. This dissertation described the development and application of peptide-based 
kinase biosensors and strategies to control enzyme activities by light. First, we developed 
a highly sensitive peptide-based biosensor that employs capillary electrophoresis to 
measure Src activity in prostate cell lysates as well as in single living cells. Our studies 
revealed that there is a direct correlation between cell aggressiveness and the fraction of 
cellular Src that is in the active state. We also determined that pTyr-527 level of Src is a 
poor indicator of inactive Src. In addition, we have demonstrated that two or more 
kinases can be simultaneously monitored using this technique. Second, aimed at 
unraveling the distinct roles of the Src family kinases Fyn and Lck in T cell activation, 
we developed a highly selective, potent, and light-deactivatable Fyn inhibitor. This 
inhibitor provides a way of selectively activating Fyn kinase by light. We have also 
discovered that attaching a profluorescent dye rendered this peptide cell permeable. Third, 
we described a new strategy for the construction of a profluorescent light-activatable 
iv 
 
cAMP-dependent protein kinase (PKA) via active site-directed peptide-based affinity 
labeling. This modified PKA displays minimum catalytic activity and low fluorescence. 
Light illumination restored enzymatic activity and induced stress fibers lose in living 
cells. A 6.2-fold fluorescence enhancement was also observed. 
The strategies developed in these studies provided powerful tools to elucidate the 
relationship of kinase activity with disease stages and the complex cell signaling 
networks. With these tools in hand, we are hoping to advance our knowledge of a basic 
biological phenomenon as well as providing future diagnostic tool for cancer patients. 
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
Structure and Regulation of Src Family Kinases 
Src kinase family members.  Protein tyrosine kinases (PTKs) play central roles 
in cell signaling pathways by catalyzing phosphoryl transfer from ATP to the tyrosine 
residues on the protein substrates. Based on sequence homology, the 90 identified 
tyrosine kinases are divided into the receptor PTK family (58 members) and the non-
receptor PTK family (32 members). Src kinase family is one of the 10 subfamilies further 
divided from the non-receptor PTK family, and has attracted much attention (Robinson et 
al., 2000). To date, there are over 10,000 papers published that involve the study of Src 
family kinases (SFKs). The 9 members of Src kinase family are: Src, Fyn, Lck, Hck, Blk, 
Lyn, Fgr, Yes, and Yrk. Members of this family are expressed in different cell types as 
listed in Table 1.1 (Parsons and Parsons, 2004; Benati and Baldari, 2008).  
Src kinase 
family member 
Pattern of expression Isoforms 
Src Ubiquitous Neuron specific isoforms 
Yes Ubiquitous  
Yrk Ubiquitous  
Fyn Ubiquitous T cell specific isoform (FynT) 
Lck T cells, NK cells, brain  
Blk B cells  
Lyn B cells, myeloid cells, brain Two alternatively spliced forms 
2 
 
Fgr B cells, myeloid cells  
Hck Myeloid cells Two different translational starts 
(Parsons and Parsons, 2004; Benati and Baldari, 2008) 
Table 1.1  Cell type specific expression of Src family kinases.  
Src family kinase domain structure.  SFKs share a conserved multidomain 
structure that contains SH1 (kinase domain), SH2 (phosphotyrosine containing sequence 
binding domain), SH3 (proline-rich sequence binding domain) and SH4 (membrane 
targeting region) domains. SFK also has a divergent “unique” domain between SH4 and 
SH3 domains (Fig. 1.1) (Boggon and Eck, 2004). The kinase domain (SH1) is composed 
of the N-terminal lobe and the C-terminal lobe. ATP binding and phosphoryl transfer 
occur at the cleft between these two lobes. The C-terminal lobe contains a peptide 
substrate binding site and an activation loop, where the critical regulatory tyrosine 
residue (Tyr-416 in Src) resides (Xu et al., 1997).  
The SH2 domain has a highly conserved recognition pocket for phosphorylated 
tyrosine residue (pTyr), and a more divergent hydrophobic residue binding pocket that 
specifically recognize different pTyr containing sequences. The preferred SH2 domain 
binding sequence for SFKs is pTyr-Glu-Glu-Ile (Eck et al., 1993). SH2 domains serve as 
protein-protein recognition and interaction modules, mediating important regulatory 
events in cell signaling pathways.  
The SH3 domain was initially characterized as a β-barrel structure that comprises 
the “PxxP” type II helix recognition site (Feng et al., 1994). However, recent studies have 
found that interaction of SH3 domain with other signaling molecules is not limited to 
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proline-rich sequences (Jia et al., 2005; Li, 2005; Kaneko et al., 2008), suggesting a much 
more diverse role of SH3 domain in cell signal transduction. 
The N-terminal membrane localization region (SH4) in SFKs contains a 
consensus Met-Gly-Cys sequence for myristoylation and palmitoylation. The lipid 
modification is necessary for the localization of SFKs to the plasma membrane (Resh, 
1999). The “unique” domain is different for each Src family members, but its function for 
most members is still unclear. However, the unique domain of Lck kinase has been 
shown to contain a “CxxC” motif that mediates interactions of Lck with T cell 
coreceptors CD4 and CD8 (Shaw et al., 1990; Turner et al., 1990), and also regulates 
selection of Lck specific substrates and biological functions of T cells (Carrera et al., 
1995). 
 
 
(Boggon and Eck, 2004; Benati and Baldari, 2008) 
 
Figure 1.1  Domain structure of Src family kinases. 
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Src family kinase activity regulation. The widely accepted model of SFKs 
activity regulation is based on the phosphorylation and dephosphorylation of two critical 
residues, tyrosine 416 and 527 (p60Src, will be used in this chapter to indicate the 
equivalent sites in SFKs). Tyr-416 is located in the activation loop of kinase domain, and 
Tyr-527 is located in the C-terminal tail. Phosphorylation of Tyr-527 is catalyzed by C-
terminal Src kinase (CSK). The crystal structures (Fig. 1.2) of the autoinhibited Src 
kinase showed that pTyr-527 docks into the SH2 domain phosphotyrosine recognition 
pocket, which facilitates the SH3 domain to form intramolecular interaction with the 
polyproline-type II helix of the SH1-SH2 linker region and also the N-lobe of kinase 
domain. As a consequence of the SH3 interaction, the two lobes of the kinase domain are 
pushed closer, and results in blocking of ATP binding cleft and burying of Tyr-416. 
Switching to the active conformation is induced either by dephosphorylation of pTyr-527 
or SH2 and SH3 domain binding partners, or a combination of the two. As a result, the 
SFKs employ an “open” conformation, and Tyr-416 becomes available for 
autophosphorylation (Boggon and Eck, 2004; Benati and Baldari, 2008). 
          
Figure 1.2  The structures of inactive and active Src family kinases. 
Reprinted from Titus, J Boggon and Michael, J Eck. (2004). Structure and regulation of Src family 
kinases. Oncogene 23, 7918-7927. © 2004 Nature Publishing Group, used with permission.   
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The SFK activity regulation model described above is based on the crystal 
structures of N-terminal truncated forms of SFKs. Therefore, the position and role of 
myristoylation and palmitoylation in full-length SFKs is not clear. Resh and co-workers 
have recently found that myristoylation and membrane association positively regulate Src 
kinase activity, but render it more susceptible to ubiquitin-mediated degradation than 
their nonmyristoylated counterpart (Patwardhan and Resh, 2010). This confirmed the 
previous findings by Hakak et al. that activation of Src increase the extent of 
polyubiquitination (Hakak and Martin, 1999). However, their study also suggested that 
membrane binding plays a role in Src activation. They proposed that myristoylation 
mediates insertion and alignment of Src to lipid bilayers, which may facilitate an optimal 
conformation for Tyr-416 phosphorylation and kinase activity (Fig. 1.3) (Patwardhan and 
Resh, 2010). 
             
Figure 1.3  The activation of Src family kinases. 
Reprinted from Margaret, C. Frame. (2002). Src in cancer: deregulation and consequences for cell 
behaviour. Biochimica et Biophysica Acta 1602, 114-30. © 2002 Elsevier Science, used with 
permission.   
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SFKs activity is often assessed by the phosphorylation levels of Tyr-416 and Tyr-
527. Higher pTyr-416 level indicates more active Src, and pTyr-527 indicates inhibited 
Src. However, the SFKs activity regulation model described above suggests that SFKs 
are activated through dissociation of the SH2 and SH3 domains from the kinase domain. 
Therefore, interaction of the SH2 and SH3 domains with higher affinity binding partners 
should be able to generate an active kinase without dephosphorylating pTyr-527. Indeed, 
a short pTyr containing peptide that binds to Src SH2 domain is able to enhance kinase 
activity (Liu et al., 1993). Knight and co-workers have determined that 20% kinase 
activity is retained in Src kinase that consists of the pTyr-527-SH2 complex and pTyr-
416. Furthermore, Src kinase activity can also be regulated by phosphorylation on serine 
and threonine residues. Lydon et al. showed that phosphorylation by serine/threonine 
kinase Cdc2 on Thr-34, Thr-46, and Ser-72 partially activates pTyr-527 containing Src 
kinase (Roskoski, 2005). Due to the complex phosphorylation and conformational 
regulation of SFKs, their activity should not be assessed solely by Tyr-416 and Tyr-527 
phosphorylation levels. 
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Src Family Kinase Signaling  
Src family kinase signaling in cancers.  Src family kinases have been implicated 
in many types of cancers. In colon cancer, a mutation that results in a C-terminal tail 
truncated Src kinase was identified, which leads to enhanced kinase activity and cancer 
metastasis (Irby et al., 1999). However, despite this finding, genetic mutations of SFKs 
are rarely detected in cancers. The major association of SFKs with cancers is through 
changes in protein expression, phosphorylation, and enzymatic activity. These changes 
have been observed in a variety of human malignancies, including prostate cancer, breast 
cancer, colorectal cancer, lung cancer, pancreatic endocrine tumor and hematologic 
malignancies (Benati and Baldari, 2008; Kim et al., 2009). 
SFKs interplay with receptor tyrosine kinases to regulate cancer cell 
proliferation and survival.  SFKs play important roles in cancer cell signaling through 
bidirectional interaction with multiple receptor tyrosine kinases (RTKs) and downstream 
signaling proteins. These RTKs include epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDGFR), insulin-like growth factor 1 receptor 
(IGFR-1), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor 
receptor (VEGFR), hepatocyte growth factor receptor (HGFR) and others (Bromann et al., 
2004; Kim et al., 2009). Src is believed to associate with activated RTKs through its SH2 
domain, thereby releasing the inhibitory intramolecular conformation, and allowing the 
enzyme to adopt an open conformation that leads to Tyr-416 phosphorylation and 
increased catalytic activity. Activated Src not only regulates downstream proteins, but 
also reciprocally phosphorylates and regulates RTKs, particularly EGFR, PDGFR and 
IGFR-1 (Benati and Baldari, 2008).  
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The synergistic roles played by EGFR and Src may have particularly important 
clinical relevance since both tyrosine kinases are frequently overexpressed in breast 
cancer (Abram and Courtneidge, 2000). Studies have shown that Src tightly associates 
with activated EGFR and is required for EGFR induced mitogenesis. Overexpression of 
Src can increase EGF-stimulated DNA synthesis and tumor cell proliferation (Belsches et 
al., 1997; Kong et al., 2003). Other studies also indicated a role of SFKs in growth factor 
stimulated DNA synthesis and mitogenesis, although the requirement of SFKs may 
depend on cell types and the cellular context in the studies (Bromann et al., 2004). 
Src signaling in cancer cell migration and invasion.  Cancer patients often 
suffer from metastasized tumors. Much attention has been devoted for developing 
diagnostics and therapeutics for metastatic cancer. In order for tumor cells to become 
metastatic, they need to acquire abilities to migrate, degrade the extracellular matrix 
(ECM), invade the stroma and enter the lymph or vascular system to reach a distant site 
(Geho et al., 2005). SFKs not only support tumor cell survival and mitogenesis during 
local and metastatic growth, but have a more profound role in reorganizing actin cell 
cytoskeleton, disrupting cell-cell and cell-matrix adhesion, altering cell morphology and 
ultimately promoting cell migration and invasion.  
Integrins are transmembrane receptors that cluster in specific cell-matrix 
adhesions to organize ECM and cell cytoskeleton, and interact with several structural and 
signaling proteins including Src, focal adhesion kinase (FAK), paxillin, talin, tensin and 
others (Berrier and Yamada, 2007). Integrin-mediated adhesion induces FAK 
phosphorylation, which creates a binding site for Src SH2 domain (Mitra and Schlaepfer, 
2006). The cytoplasmic tail of β3 integrins can also directly interact with Src SH3 
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domain, promoting Src activation (Huveneers and Danen, 2009). Therefore, Src is 
recruited and activated at the adhesion and protrusion leading edge during cell migration. 
Activated Src then recruits and activates the scaffold protein p130Cas, which binds 
Dock180 and ELMO1 through association with the adaptor protein Crk. The Dock180-
ELMO1 complex serves as a guanine-exchange factor to activate Rac1 and induce actin-
driven cell protrusions (Huveneers and Danen, 2009). Src also mediate suppression of 
Rho through phosphorylating p190RhoGAP, which is important for relieving contractile 
forces during migration. At the cell’s trailing edge, Src recruits ERK/MAPK and calpain, 
which induces proteolytic cleavage to promote adhesion disassembly and cell-matrix 
detachment (Fig. 1.4) (Guarino, 2009). 
               
Figure 1.4  Role of Src during cell migration. 
Reprinted from Marcello, Guarino. (2010). Src signaling in cancer invasion. Journal of Cellular 
Physiology 223, 14-26 © 2010 Wiley-Liss, Inc., used with permission.   
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Src also induces activation of the PI3K/Akt pathway either through direct binding 
of PI3K to the Src SH3 domain or phosphorylation of PI3K. PI3K plays a central role in 
cell migration by generating asymmetrical signaling that establishes cell polarity. Src 
mediated PI3K/Akt activation can also enhance tumor cell survival during growth, 
invasion and metastasis due to the anti-apoptotic effect of Akt (Guarino, 2009). 
Epithelial cells become migratory through the epithelial-mesenchymal transition 
(EMT), during which the cell-cell junctions are disrupted. Src is required for EGF- and 
HGF-induced EMT by phosphorylating the E-cadherin-β-catenin complex, thus altering 
the interaction between the two proteins and thereby interfering with E-cadherin 
functionality (Fig. 1.5) (Behrens et al., 1993; Frame, 2002). Furthermore, for tumor cells 
to invade, they not only need to acquire the migratory phenotype, but also have to 
translocate through matrix barriers. Src is known to mediate “mesenchymal-type” 
invasion by promoting the expression of matrix degrading proteases, such as 
metalloproteinases (MMPs) (Kuo et al., 2006; Wang and McNiven, 2012). 
                     
Figure 1.5  Src mediate EGF- and HGF-induced epithelial-mesenchymal transition 
(EMT) and cell migration and invasion. 
Reprinted from Margaret, C. Frame. (2002). Src in cancer: deregulation and consequences for cell 
behaviour. Biochimica et Biophysica Acta 1602, 114-30. ©2002 Elsevier Science, used with 
permission.    
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The Interplay of Src with sex steroid receptors in cancer.  Sex steroid 
hormones including estrogen, progesterone and androgen are key regulators in the 
development and progression of endocrine-related cancers. These hormones function 
through estrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR), 
respectively. These receptors are members of the nuclear receptor (NR) superfamily, and 
function as transcription factors to regulate gene expression (Gao et al., 2002). Src has 
been suggested to play a role in hormone receptor signaling and resistance. Studies have 
shown that blocking Src interaction with AR or ER strongly inhibits prostate cancer or 
breast cancer growth (Saad and Lipton, 2010). Prostate and breast cancer patients who 
receive hormone-deprivation/blocking therapies often develop androgen-independent 
prostate cancer or antiestrogen-resistant breast cancer, which results in a poor prognosis. 
Src kinase has been demonstrated to contribute to hormone-independent tumor growth by 
transactivating AR/ER mediated signaling through other mechanisms, including growth 
factor and cytokine receptor activation (Hiscox et al., 2006; Mellado et al., 2009). 
Moreover, active Src kinase can also drive the transition of prostate cancer from the 
androgen-dependent to -independent type (Unni et al., 2004).  
Src family kinases in hematologic malignancies.  Src family members are also 
key players in hematologic malignancies. Increased Hck and Lyn activities are evident in 
Bcr-Abl positive cells (Danhauser-Riedl et al., 1996). Overexpression of Lck has been 
found in acute myeloid leukemia (AML) and T-adult lymphoblastic leukemia (T-ALL) 
(Benati and Baldari, 2008). 
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Src Family Kinases in T-Cell Signaling 
Lck and FynT (the T cell specific isoform of Fyn) are the predominant SFKs 
found in T cells. They are believed to have overlapping and distinct functions during T 
cell receptor (TCR) proximal signaling. Lck associates with CD4 and CD8 receptors 
through cysteine residues in the “unique” domain (Turner et al., 1990; Kim et al., 2003), 
whereas the “unique” domain of FynT interacts with the TCR-CD3 complex (zur Hausen 
et al., 1997). The SH2 and SH3 domains of Lck and FynT also exhibit different binding 
specificities. Different molecules have been shown to interact with Lck or FynT, as 
demonstrated by coimmunoprecipitation experiments (Table. 1.2) (Zamoyska et al., 
2003).  
 
Table 1.2  Signaling molecules associated with Lck and FynT in T cells. 
Adapted from Zamoyska, R., Basson, A., Filby, A., Legname, G., Lovatt, M., and Seddon, B. 
(2003). The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival 
and activation. Immunological Reviews 191, 107–118. © 2003 Blackwell Munksgaard, used with 
permission. 
 
Activities of Lck and FynT are not only regulated by domain binding, but also by 
phosphorylation and dephosphorylation. Phosphatase CD45 is responsible for the 
dephosphorylation of both pTyr-416 and pTyr-527. pTyr-416 can also be 
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dephosphorylated by other phosphatases including PEP, PTP-PEST and SHP-1 (Salmond 
et al., 2009). Lck also contains a serine phosphorylation site that is not present in FynT. 
Serine/threonine kinase MAPK/ERK phosphorylation of this site leads to changes in Lck 
SH2 binding affinity to phospho-proteins (Stefanová et al., 2003). 
The different roles of Lck and FynT can also be attributed to their different 
cellular localizations. Lck is often found at plasma membrane, whereas FynT is 
intracellular and colocalizes with the centrosome and microtubules (Ley et al., 1994). It is 
still unclear how each kinase is specifically recruited and activated upon T cell 
stimulation. One possible mechanism proposed by Julius and co-workers is that Lck is 
activated outside of lipid rafts, and then recruited into rafts (Filipp et al., 2003). This 
translocation is required for Fyn colocalization and activation (Filipp et al., 2008) (Fig. 
1.6).  
 
 
Figure 1.6  Lck and FynT recruitment and activation upon TCR stimulation. 
Reprinted from Palacios, E.H., and Weiss, A. (2004). Function of the Src-family kinases, Lck and 
Fyn, in T-cell development and activation. Oncogene 23, 7990–8000. © 2004 Nature Publishing 
Group, used with permission. 
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Upon T cell stimulation, activated Lck phosphorylate CD3 and ζ-chain ITAMs, 
leads to recruitment and activation of ZAP-70, which then phosphorylates an adapter 
protein LAT. LAT is central to the recruitment of multiple signaling molecules that leads 
to T cell activation. Activated FynT is believed to also contribute to activating some of 
these pathways, and can partially compensate for loss of Lck (Samelson, 2002). However, 
FynT is also sufficient to initiate some signaling pathways, as demonstrated in studies 
using Lck deficient cell lines. For example, FynT alone can activate MAPK/ERK or 
PI3K upon TCR stimulation (Lovatt et al., 2006; Salmond et al., 2009).  
In addition to positive regulation of TCR signaling, Lck and FynT also play a 
feedback inhibition role in T cell signaling pathways. Stimulation of TCR and 
coreceptors in a Fyn deficient T cell caused more IL-2 production and faster cell 
proliferation. This hyperactivity of Fyn-deficient T cells was not observed by TCR 
activation (anti-CD3 stimulation) alone, which suggests the involvement of Lck in the 
hyperactive phenotype (Filby et al., 2007). Moreover, FynT phosphorylation of PAG, 
which is a transmembrane adaptor protein, is required for recruiting CSK to the vicinity 
of SFKs, indicating a negative feedback loop (Yasuda et al., 2002; Davidson et al., 2007). 
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Sensing Kinase Activity 
As the complex regulation mechanisms of kinases and their important roles in cell 
signaling and diseases are revealed, the ability to measure kinase activity in living cells 
and understand precise regulation in a spatiotemporal manner has become critical. 
Therefore, biosensors and “caged” enzymes aiming to visualize or/and control kinase 
activity, dynamics and localization have been developed.  
FRET-based sensors.  Fluorescence resonance energy transfer (FRET) is the 
transfer of energy from the donor to the acceptor fluorophore, which strongly dependents 
on donor and acceptor distance and orientation. One major class of FRET-based kinase 
biosensors is based on the phospho-amino acid binding induced orientation change 
between the donor and acceptor. When the target kinase is activated, the substrate 
sequence of the biosensor become phosphorylated, and then binds to the adjacent 
phospho-amino acid binding domain. As illustrated in Fig. 1.7, this binding result in an 
orientation change of the fluorescent proteins, thus inducing a FRET change 
(VanEngelenburg and Palmer, 2008).  
                     
Figure 1.7  FRET-based kinase sensor based upon phosphorylation induced 
conformational change.  
Reprinted from VanEngelenburg, S.B., and Palmer, A.E. (2008). Fluorescent biosensors of protein 
function. Current Opinion in Chemical Biology 12, 60–65.© 2008 Elsevier Science, used with 
permission.    
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This type of FRET-based kinase sensors has been developed for a variety of 
kinases, and new biological phenomena have been discovered. Tsien and co-workers are 
among the first to develop FRET-based kinase sensors, which include sensors for Abl, 
Src, EGFR, PKB, PKC and PKA. Studies using these sensors have lead to some 
interesting findings. For example, PDGF-induced Abl activity is strongest in membrane 
ruffles (Ting et al., 2001); local mechanical stimulation induces directional and long 
range Src activation (Wang et al., 2005); phosphorylation of the PKC sensor coincides 
with calcium oscillations (Violin et al., 2003), and PKB signaling is more rapid in the 
cytosol than in the nucleus (Kunkel et al., 2005). Umezawa and co-workers also used a 
FRET based PKB/Akt sensor to discover that activated PKB localizes to subcellular 
compartments, and different stimuli triggers different localization (Sasaki et al., 2003). 
Studies using FRET sensors to monitor the activity of other kinases, including ERK 
(extracellular signal-regulated kinases) (Sato et al., 2007), JNK (Jun N-terminal kinase) 
(Pereira et al., 2011) and MAPK (mitogen-activated protein kinase) (Timm et al., 2011) 
have also been published.  
The FRET pair can also be introduced onto a kinase itself, if the kinase employs a 
conformational change upon activation. This approach has been used to monitor several 
kinases in living cells, including PKB/Akt (Calleja et al., 2003, 2007), Ca2+/calmodulin-
dependent protein kinase II (CaMKII) (Takao et al., 2005; Erickson et al., 2011), ERK2 
(Fujioka et al., 2006) and MAP kinase-activated protein kinase 2 (MK2) (Neininger et al., 
2001). 
The FRET-based kinase sensors usually give 10-35% signal change. There has 
been a significant effort to improve the response, notably by adjusting fluorophore 
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distance and orientation, or changing FRET partners (Zhang et al., 2005; Allen and 
Zhang, 2006). Although these sensors are advantageous in the aspect that they are 
genetically encoded and don’t require cellular delivery, the small FRET signal change 
and other possible issues including donor-to-acceptor stoichiometry, bleed-through and 
cross excitation, and donor/accepter orientation all lead to difficulties in designing and 
analyzing FRET-based kinase sensing (Kremers et al.).  
Fluorescent peptide-based sensors.  Peptide-based sensors are advantageous in 
that they can be easily synthesized, are relatively small, and can be modified to contain 
functional groups to achieve high affinity and specificity. The traditional way of 
assessing kinase activity using peptide substrates is radioactive ATP-based assays, where 
phosphorylation is quantified by the amount of radiolabeled gamma phosphate 
transferred to the substrate. However, these types of assays are discontinuous and require 
special handling of radioactive materials.  
In the past decade, fluorescent peptide-based kinase sensing systems have been 
developed and proved useful in biological systems. One such system is capillary 
electrophoresis with laser induced fluorescence (CE-LIF)-based kinase activity 
measurement. The synthetic peptide substrate for the target kinase is labeled with a 
fluorophore. The nonphosphorylated substrate and the kinase phosphorylated product can 
be separated and quantitatively detected by CE-LIF, therefore allowing a measurement of 
target kinase activity in cell lysate as well as in living cells. Several peptide-based sensors 
have been developed using this technique, including sensors for PKA, PKB, PKC, 
CamKII, cdc2K, Src and EGFR (Meredith et al., 2000; Rauf et al., 2010; Li et al., 2011 
and the studies described in Chapter 2). CE offers several significant advantages: high 
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resolution, high sensitivity, minimum sample consumption, high sample capacity, short 
detection time and automated high-throughput analysis (Pang et al., 2004; Wang and 
Audet, 2009). These features not only allow single cell level analysis and multiplexed 
kinase measurement, but also provide drug screening and disease diagnosis applications. 
The drawback, however, is that the assays are discontinuous. Moreover, live cell 
application requires peptide delivery and the sensors lack spatial resolution (Wang and 
Audet, 2009). 
A popular continuous peptide-based kinase sensing is based on phosphorylation 
induced fluorescence change. Because peptide sensing strategy doesn’t rely on FRET, the 
fluorescence response is generally over 100%, which can significantly improve 
sensitivity (Lawrence and Wang, 2007). The phosphorylation induced fluorescence 
change can be achieved by several mechanisms. One type of kinase sensor initially 
developed by Lawrence and co-workers and then further developed by Imperiali and co-
workers is based on chelation enhanced fluorescence (CHEF). The substrate peptides 
contain a chelation sensitive fluorophore, which exhibit enhanced fluorescence upon 
phosphate group mediated metal binding. CHEF-sensors for a variety of kinases have 
been developed, including PKC, Src, Abl, IRK, PKB, MK2, Pim2, PKA and p38α (Chen 
et al., 2002; Shults and Imperiali, 2003; Luković et al., 2008; González-Vera et al., 2009; 
Stains et al., 2011; also reviewed in González-Vera, 2012).  
Environmentally sensitive fluorophores is another strategy for developing kinase 
sensors. Most of these fluorophores exhibit weak fluorescence in aqueous solutions, but 
bright fluorescence in non-polar solvent or hydrophobic environment. One strategy is to 
place an environmentally sensitive fluorophore on the peptide substrate close to the 
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phosphorylation site. Kinase-mediated phosphorylation modifies the local polarity and 
thus induces a fluorescence change (Yeh et al., 2002b).  Another strategy utilizes the 
phopho-peptide recognition protein domains. Binding of a protein domain upon peptide 
phosphorylation will embed the fluorophore in a hydrophobic pocket, thus enhancing 
fluorescence (Wang and Lawrence, 2005). Environmentally sensitive fluorophores-
mediated kinase sensing has also been successfully applied in living cells. Hahn and co-
workers have developed a Src kinase sensor, in which a solvent-sensitive merocyanine 
dye was conjugated to a monobody that contain SH3 domain binding motif. When the 
Src kinase becomes activated, the SH3 domain is released from the “closed” 
conformation and recognized by the monobody. This binding induces a fluorescence 
enhancement of the dye, which is possibly due to the decrease in water-exposed surface 
area. Using this sensor, they found that Src kinase with an “open” conformation localizes 
to dorsal ruffles during cell protrusion (Gulyani et al., 2011). 
Another kinase induced fluorescence increase is through disruption of 
fluorescence quenching. Fluorophores can be quenched via static and collisional 
mechanisms by several amino acids, including Trp, Met, Tyr and His (Chen et al., 2010). 
This phenomenon has been used to develop kinase sensors, since phosphorylation could 
disrupt the interaction and cause fluorescence increase. Pyrene labeled sensors have been 
developed by Lawrence et al., in which up to 4.7-fold fluorescence increase was observed 
upon kinase-induced phosphorylation (Wang et al., 2006b; Wakata et al., 2008). 
Fluorophores with longer excitation and emission wavelength, such as cascade yellow, 
oregon green and cascade blue, have also been used for this type of kinase sensor and 
applied to cell-based systems (Wang et al., 2006c). The ability to use fluorophores with 
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different wavelengths also allowed the development of a multicolor sensing system for 
two or more kinases (Wang et al., 2010b). Lee and colleagues have developed another 
quenching strategy based on micelle formation. Phosphorylation introduces negative 
charges and thus disrupts the micelle, which leads to a 4-6 fold fluorescence increase 
(Sun et al., 2005). In addition, fluorescence fold change has been significantly enhanced 
(>60-fold) using a “deep quench” strategy also developed by Lawrence and co-workers. 
A quencher molecule non-covalently interacts with the substrate peptide. Kinase 
phosphorylation induces the phospho-peptide binding to a protein domain, thereby 
disrupting the quencher interaction (Sharma et al., 2007).   
Peptide-based kinase sensors have been developed rapidly over the past few years. 
However, only a few have been applied to biological systems. Current peptide-based 
kinase biosensors need to be improved in their sensitive, specificity, protease resistance 
and photophysical properties, as well as cell delivery.  
Photoactivatable (“caged”) proteins.  The complex spatial and temporal 
regulation of cell signaling networks provides a challenge in elucidating the role of 
intracellular protein activity and its affect on cellular behavior. Therefore, in the past 
decade, much attention has been given to developing photoactivatable (“caged”) proteins, 
whose activities can be spatially and temporally controlled using light in a living cell 
system. 
Several techniques have been developed to construct “caged” protein derivatives. 
The most utilized approach to cage proteins is by modifying key active site residues, 
most commonly lysine or cysteine, using photo-cleavable moieties (Fig. 1.8A). Proteins 
caged using this strategy include G-actin (Marriott, 1994), myosin (Marriott and 
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Heidecker, 1996), β-galactosidase (Golan et al., 1996) and PKG (Priestman et al., 2011). 
The difficulties commonly associated with this strategy are: (a) lack of precise control of 
modification for proteins that contain multiple reactive residues, and (b) not all proteins 
contain reactive residues that regulate enzymatic activity. Molecular biology, however, 
has provided alternative strategies that allow specific modification. One way is using site-
directed mutagenesis to introduce reactive residues (e.g., cysteine) at key active sites 
(Chang et al., 1995; Ghosh et al., 2004), or to generate single reactive residue mutant 
(Chang et al., 1998). Another strategy pioneered by Schultz and co-workers (Wang et al., 
2006a) is unnatural amino acid mutagenesis, which allows direct protein expression with 
the desired caging groups at specific sites of the target protein. A variety of proteins have 
been caged using unnatural amino acid mutagenesis (reviewed in Lee et al., 2009; 
Riggsbee and Deiters, 2010). Single key residue modification has also been described 
using an enzyme-directed caging protocol (Zou et al., 2002).  
Proteins can also be caged through expressed protein ligation (EPL). This 
approach allows synthetic small peptides that contain multiple modifications (e.g., photo-
cleavage site, fluorophores and quenchers) to ligate to proteins via native amide bond 
(Hahn and Muir, 2004; Pellois et al., 2004; Hahn et al., 2007). Another strategy of caging 
enzymes is using caged small molecule effectors (Kawakami et al., 2008; Karginov et al., 
2010; Riggsbee and Deiters, 2010; Priestman et al., 2011), or inhibitors that can be 
destroyed by light (Li et al., 2008a) (Fig. 1.8B). Several caged small molecule effectors 
have been developed to control protein expression, including caged doxycycline, 
ecdysone, estradiol, tamoxifen, and isopropyl-β-D-thiogalactoside (IPTG) (Riggsbee and 
Deiters, 2010). Nagamune et al. developed a caged PI3K SH2 domain binding peptide, in 
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which the critical tyrosyl phosphate moiety is protected by a photolabile group. 
Microinjecting this peptide into living cells and followed by UV irradiation induced light-
dependent PI3K activation (Kawakami et al., 2008). Dieters and co-workers used a caged 
rapamycin to induce protein dimerization by light in living cells (Karginov et al., 2010). 
In addition, Lawrence et al. have reported a coumarin-caged cAMP that was used in 
conjunction with nitrobenzyl-caged PKG to achieve wavelength-distinct photoactivation 
of PKA and PKG in living cells (Priestman et al., 2011). Deiters et al. have recently 
developed an inhibitor-like caging strategy, in which protein function is sterically 
blocked by bulky PEG polymers attached to lysine residues through a photo-labile linker. 
Upon UV irradiation, the PEG photocage will be removed to release the native protein 
(Georgianna et al., 2010).  
The use of light-responsive LOV (light-oxygen-voltage) domain from plant 
phototropin to cage protein activity has become popular in recent years. LOV contains an 
α helix that docks with the rest of the domain in the dark but undocks upon blue light 
(450–500 nm) irradiation. This large conformational change enables allosteric regulation 
of proteins fused to the LOV domain. Activities of proteins including Rac1 (Wu et al., 
2009), DHFR (Lee et al., 2008a) and TrpR (Strickland et al., 2008) have been controlled 
using this strategy. This approach is attractive not only because it allows genetic 
expression of the caged proteins, but also the fusion protein activity can be reversibly 
controlled in the presence and absence of light. In addition to LOV, other light-
responsive proteins such as PhyB (Leung et al., 2008; Levskaya et al., 2009), and CRY2 
(Kennedy et al., 2010) are also being used for the spatiotemporal control of cell signaling 
proteins (Fig. 1.8C). 
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Figure 1.8  Different approaches to construct “caged” proteins. 
(A) Key residues modified by photo-cleavable groups. (B) Control of protein function by 
light using caged small molecule effectors. (C) Reversible regulation of protein activity 
by light-responsive domains.  
Adapted from Chad W. Riggsbee, Alexander Deiters. (2010). Recent advances in the 
photochemical control of protein function. Trends in Biotechnology. 28, 468-475. © 2010 Elsevier, 
used with permission. 
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CHAPTER II 
SRC KINASE ACTIVITY PROFILING IN PROSTATE CANCER: A CORRELATION 
WITH CANCER CELL INVASIVENESS 
 
Conventional strategies for identifying the biochemical basis of tumorigenesis and 
metastasis rely upon the search for aberrant up- (or down-) regulated genes and proteins. 
Although this approach has lead to life-saving discoveries (Gora-Tybor and Robak, 2008), 
many areas of cancer diagnosis, treatment, and prognosis remain intractable. For example, 
a majority of men diagnosed with prostate cancer (CaP; e.g. >200,000 American 
men/year), a typically slow growing disease, will eventually die from other disorders. For 
these patients, treatment is both unnecessary and expensive, with the cost of a typical 
radical prostatectomy running approximately $5000 - $7500 (based on data from 2007) 
(Bolenz et al., 2010). On the other hand, a significant fraction of CaP patients will find 
themselves dealing with the deadly metastatic form of the disease: approximately 27,000 
American men die from CaP each year (Wolf et al., 2010). The absence of clear-cut 
biochemical markers precludes the design of a satisfactory treatment protocol at the time 
of diagnosis. In short, a burning and unresolved issue in the field of CaP is how to 
distinguish between the benign and deadly forms of the disease at the time of diagnosis. 
Metastasis is dependent, in part, on the ability of cells to separate from the parent 
tumor and migrate toward growth factor gradients emanating from nearby blood vessels. 
Migration is a highly spatial phenomenon mediated by the directed formation of 
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invadopodia, protease-active protrusions displayed by metastatic cancer cell lines and by 
patient-derived tumor cells (Buccione et al., 2009). Invadopodia promote the breakdown 
of the extracellular matrix in a machete-like fashion, a behavior required for the 
subsequent invasion of surrounding tissue. The protein tyrosine kinase Src is both 
sufficient and necessary for invadopodia formation and function (Bowden et al., 2006; 
Buccione et al., 2009; Kelley et al., 2010). This is due, at least in part, to the Src kinase-
mediated phosphorylation of cortactin, an action that triggers the cofilin-promoted 
assembly of F-actin in invadopodia (Oser and Condeelis, 2009; Mader et al., 2011). In 
addition, Src is known to play a critical role in promoting protrusions at the leading edge, 
an essential element of migratory behavior that is likewise a cofilin-dependent process. 
Recently, it has been proposed that the cofilin pathway in metastatic cells is globally 
inhibited, yet contains spatially-localized pockets of dynamic activity (Soon, 2007). In 
short, the intracellular topography of this key signaling pathway may form the 
biochemical basis of metastatic potential. In addition to invasion, Src has also been 
implicated in the transition to and maintenance of androgen-independent growth, another 
hallmark of aggressive CaP (Fizazi, 2007; Tatarov et al., 2009).  
Given the critical role that Src plays as a trigger for invadopodia formation and 
function as well as in directing cell movement, we wondered if a relationship exists 
between Src kinase activity and the known invasive behavior of various prostate cell lines. 
Furthermore, we decided to place a constraint on the fashion by which we addressed this 
conjecture: can we devise and employ a method to assess Src activity that might 
eventually prove applicable to patient samples? In particular, prostate biopsies furnish 
only a limited supply of cells. Furthermore, primary cells are challenging to grow in 
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culture and difficult to transfect, thereby placing significant demands on any method that 
seeks to assess the kinetic properties of protein kinases. Although there are a number of 
available methods to sample protein kinase activity, including a variety of genetically-
encoded and peptide-based probes that detect kinase activity by a fluorescence change, 
these are unlikely to be useful in evaluating kinase activity in primary cells (Rothman et 
al., 2005; Lawrence and Wang, 2007; Sharma et al., 2008; Li et al., 2008b; Uri et al., 
2010; Newman et al., 2011). With these challenges in mind, we have developed a 
capillary electrophoresis (CE)-based strategy for sampling Src kinase activity. CE is an 
extraordinarily sensitive method (Kovarik and Allbritton, 2011), which is essential when 
sample quantity is limited (e.g. patient biopsies). Furthermore, CE instruments are 
commercially available that are operated in clinical labs (Jabeen et al., 2006). In this 
project, we developed a selective and sensitive approach for quantifying the enzymatic 
activity of the Src kinase in large cell populations as well as in single cells. Furthermore, 
we evaluated the relationship between Src activity and cellular invasiveness across a 
series of normal and cancerous prostate cell lines and identified a positive correlation 
between fractional enzymatic activity and invasiveness. 
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Materials and Methods 
Peptide synthesis.  Analytical grade reagents N,N-dimethylformamide (DMF), 
dichloromethane (DCM), N,N-diisopropylethylamine (DIPEA), acetonitrile (ACN), 
trifluoroacetic acid (TFA) and other common reagents were purchased from Fisher or 
Sigma-Aldrich. Fmoc amino acids, O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU), N-hydroxybenzotriazole (HOBT) and 
NovaSyn TGR resins were obtained from NovaBiochem. Fmoc-Orn(Aloc)-OH was 
obtained from Bachem. 5-carboxyfluorescein (5-FAM) was purchased from Anaspec. 
The non-phosphorylated peptide–resin Fmoc-Orn(Aloc)-Glu(OtBu)-Glu(OtBu)-
Glu(OtBu)-Ile-Tyr(tBu)-Gly-Glu(OtBu)-Phe-Orn(Aloc)-amide-Resin and the 
phosphorylated peptide–resin Fmoc-Orn(Aloc)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-
Tyr(PO(OBzl)OH)-Gly-Glu(OtBu)-Phe-Orn(Aloc)-amide-Resin were synthesized using 
a standard Fmoc peptide synthesis protocol on the Prelude automatic peptide synthesizer 
(Protein Technologies). Briefly, amino acid (5 equiv), HCTU (5 equiv) and DIPEA (10 
equiv) were mixed with TGR resin in DMF and reacted with nitrogen bubbling mixing 
for 10 min at room temperature. Fmoc deprotection was achieved by using 20% 
piperidine in DMF for 20 min. The allyloxycarbonyl (Aloc) protecting group on the 
ornithine (Orn) residues was selectively removed with 3 equivalent of tetrakis 
(triphenylphosphine) palladium [Pd(PPH3)4] in chloroform/acetic acid/N-
methylmorpholine (37:2:1). The Orn residues were then acetylated using acetic 
anhydride/DIPEA (4:1) and the N-terminal Fmoc protecting group was subsequently 
removed. The free N-terminus was then exposed to 5-FAM (5 equiv), HOBT (10 equiv) 
and N,N’-diisopropylcarbodiimide (DIC, 15 equiv) in DMF overnight, followed by 
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incubating with 30% piperidine for 15 min. The peptides were cleaved with 
TFA/H2O/TIS (triisopropylsilane) (95:2.5:2.5) and purified via HPLC (Waters), and their 
structures confirmed by ESI-Mass Spectrometry (Agilent Technologies). C81H97N13O27 
(peptide 1) calculated Mass: 1684.7, found (ESI+) 1684.0 and C81H98N13O30P (peptide 2) 
calculated Mass 1764.7, found 1764.0. 
Cell permeable Src sensor peptide 3 was prepared by mixing free N-terminal 
amine containing peptide with 1.5 equivalent of carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE, AnaSpec) in anhydrous DMF, and react in the presence of 
10 equiv of anhydrous DIPEA for 2 h. Reaction mixture was then purified by HPLC and 
confirmed by ESI-MS. C85H103N13O29 (peptide 3) calculated Mass: 1770.8, found 1768.2.  
Peptides 9-14 were synthesized in a similar fashion described above. Briefly, the 
peptide backbones were prepared using a peptide synthesizer, and followed by 5-FAM 
coupling on the free N-terminal amine. All the peptides were HPLC purified and 
confirmed by ESI-MS. C63H67N9O21 (peptide 9) calculated Mass: 1286.2, found 1285.6; 
C65H69N9O23 (peptide 10) calculated Mass: 1344.3, found 1343.8; C64H69N9O21 (peptide 
11) calculated Mass: 1300.3, found 1300.0; C66H71N9O23 (peptide 12) calculated Mass: 
1358.3, found 1357.8; C63H67N9O21 (peptide 13) calculated Mass: 1286.2, found 1286.0; 
C63H69N9O19 (peptide 14) calculated Mass: 1256.3, found 1256.0. 
Cell culture and cell lysate preparation.  All cell lines were acquired from 
ATCC and grown in a humidified incubator at 37 ˚C with 5% CO2. PZ-HPV-7, RWPE1, 
WPE1-NA22, WPE1-NB14, WPE1-NB11 and WPE1-NB26 cell lines were cultured in 
Keratinocyte Serum Free Medium (K-SFM) supplied with 0.05 mg/mL bovine pituitary 
extract (BPE) and 5 ng/mL epidermal growth factor (EGF) (all provided as a kit from 
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Invitrogen), and 1% penicillin/streptomycin (P/S; Invitrogen). 22Rv1 cells were cultured 
in RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine 
serum (HI-FBS, Invitrogen) and 1% P/S. DU145 cells were cultured in Eagle’s Minimum 
Essential Medium (EMEM, ATCC) supplemented with 10% HI-FBS and 1% P/S. PC3 
cells were cultured in F-12K medium (ATCC) supplemented with 10% HI-FBS and 1% 
P/S. Cell lysates were prepared as followings: confluent cells were first trypsinized and 
collected into 15 mL tubes and then washed 3 times with 10 mL ice cold Dulbecco's 
phosphate-buffered saline buffer (DPBS, no calcium, no magnesium, Invitrogen). The 
cells were lysed by M-PER mammalian protein extraction reagent mixed with 5/100 (v/v) 
Halt protease and phosphatase inhibitor cocktail EDTA-free (Thermo Fisher Scientific), 
and rotated for 10 min at 4 ˚C. Cell debris was removed by centrifuging samples at 
14,000 x g for 10 min at 4 ˚C. The total protein concentrations were determined by 
comparing to known concentrations of bovine serum albumin (BSA) using the Dc Protein 
assay (Bio-Rad). 
Capillary electrophoresis.  Capillary electrophoresis was performed on a 
ProteomeLab PA800 system equipped with a laser-induced fluorescence (LIF) detector 
(Beckman Coulter). The LIF was excited using the 488 nm argon laser. A fused-silica 
capillary (30/20 cm total/effective length, 50/360 µm inner/outer diameter) was used for 
separation (Polymicro Technologies). Prior to installation, capillaries were pretreated 
with 0.1 M NaOH for 12 h, distilled water for 1 h, 0.1 M HCl for 6 h and distilled water 
again for 12 h. For samples containing Src or/and Akt substrates, the concentrated 
samples were diluted in 100 mM Borate/100 mM SDS buffer at pH 7.7 (final volume no 
less than 20 µL) and hydrodynamically injected and separated at 25 ˚C at a constant 
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voltage of 12 kV. The running buffer was 100 mM Borate/100 mM SDS buffer at pH 7.7. 
For samples containing EGFR substrates, the concentrated samples were diluted in 100 
mM Borate buffer at pH 7.5 and hydrodynamically injected and separated at 25 ˚C at a 
constant voltage of 12 kV. The running buffer was 140 mM Borate/70 mM SDS buffer at 
pH 7.7. Before each run, the capillary was rinsed with 0.1 M NaOH, distilled water, and 
then the running buffer for 2 min under 20 psi pressure. Data was collected and analyzed 
using 32 Karat Software (Version 8.0, Beckman Coulter).  
Protein kinase phosphorylation assay. Kinase assay reagents including 4-
morpholinepropanesulfonic acid (MOPS), ethylenedinitrilotetraacetic acid (EDTA), 
magnesium chloride (MgCl2) and adenosine 5′-triphosphate disodium salt hydrate (ATP) 
were purchased from Sigma Aldrich. The pure Src kinase phosphorylation assays were 
performed with a total volume of 40 µL from the following stock solutions: 30.9 µL of 
H2O, 0.5 µL of 1.14 mM substrate stock solution, 4 µL of 10X Src kinase reaction buffer 
(80 mM MOPS, 2 mM EDTA, 40 mM MgCl2, pH 7.0), 0.6 µL of 100 ng/µL active Src 
kinase (Millipore 14-326), 4 µL of 10 mM ATP. Final concentration of the assay solution 
was 8 mM MOPS, 0.2 mM EDTA, 4 mM MgCl2, 1.5 ng/µL Src kinase, 14.25 µM 
substrate, and 1 mM ATP. Assays were initiated by adding ATP. At each time point, 2 
µL of the reaction mixture was removed and diluted with 8 µL 0.1 M HCl to stop the 
reaction.  
The Src and Akt kinase phosphorylation assays were performed in a similar 
fashion, but the final concentration of the assay solution was 8 mM MOPS, 0.2 mM 
EDTA, 4 mM MgCl2, 0.25 ng/µL Src kinase or/and Akt1 kinase (S473D, Millipore 14-
453), 15 µM Src substrate or/and Akt substrate, and 1 mM ATP. The EGFR and Src 
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kinase phosphorylation assays were performed using a total assay volume of 15 µL, and 
the final concentration of the assay solution was 8 mM MOPS, 0.2 mM EDTA, 4 mM 
MgCl2, 10 mM MnCl2, 0.1 µg/µL BSA, 0.05 mM DTT, 1.7 ng/µL Src kinase or 6 ng/ µL 
EGFR kinase (Millipore 14-531), 40 µM Src substrate or EGFR substrate, and 1 mM 
ATP. 
Cell lysate phosphorylation assays were also performed similarly as described 
above under the following conditions: 2.5 µg/µL cell lysate, 6.75 mM Tris (pH 7.5), 1 
mM ATP, 4 mM MgCl2, 57 µM substrate in the absence of presence of different 
concentrations of tyrosine kinase inhibitors Gleevec (imatinib mesylate) or AZD0530 
(Selleck Chemicals). Assays were initiated by adding substrate(s).  
Western blot experiments.  Primary antibodies Src (36D10): #2109, Yes: #2734, 
Phospho-Src Family (Tyr416): #2101, Phospho-Src (Tyr527): #2105, and α-tubulin 
(DM1A): #3873 were purchased from Cell Signaling Technology; anti-Fyn: 610163 and 
anti-Lck: 551047 were purchased from BD Pharmingen Biosciences; anti-Lyn (H-6): sc-
7274 was obtained from Santa Cruz Biotechnology. Secondary antibodies (Amersham 
ECL anti-rabbit or anti-mouse IgG, horseradish peroxidase linked species specific whole 
antibody from donkey) were obtained from GE Healthcare. SDS-PAGE gel 
electrophoresis was performed using NuPage 4-12% Bis-Tris precast gel (Invitrogen), 
running at 200 V for 50 – 60 min. Gels were transferred to PVDF membranes using iBlot 
dry blotting system (Invitrogen) for 7 min. Blocking, antibody incubation, and washes 
were performed on SNAPid protein detection system (Millipore). Specifically, the 
membranes were first blocked using 0.5% non-fat milk in 1X PBS buffer supplemented 
with 0.1% Tween-20 (PBST) for 1 min. After removing the blocking buffer, the 
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membranes were incubated with primary antibodies for various times (non-phospho 
antibodies were diluted 1.7:1000 in blocking buffer and incubated for 15 min (X2); 
phospho-antibodies were diluted 1.7:1000 in PBST and incubated for 3 h. The 
membranes were washed with PBST 3 times following manufacture’s instruction. Then 
secondary antibodies (1:1000 dilution in blocking buffer for non-phospho protein 
detection; 1:1000 dilution in PBST for phospho-protein detection) were applied for 15 
min. The membranes were subsequently washed with PBST (X3), 0.5% NaCl (X3) and 
PBS (X3). The blots were detected by Amersham ECL Plus (GE Healthcare) and the 
chemiluminescence images were obtained by the FluoChemFC2 system (Alpha Innotech). 
The densitometry analysis of the bands was performed using the AlphaView software.  
Immunodepletion of Src kinase from cell lysates.  A Pierce Classic IP kit was 
employed for these experiments. The immune complex was formed by mixing (via 
rotation) 500 µg of cell lysate with 5 µg of Src antibody Src (36D10): 2109 or 5 µg 
bovine serum albumin (BSA) as control overnight at 4 ˚C. The immune complex was 
then captured by mixing (via rotation) the cell lysate-antibody mixtures with Pierce 
protein A/G agarose; the BSA control was mixed with Pierce control agarose resin for 1 h 
at 4 ˚C. Both treatments (with antibodies and with bovine serum albumin) were 
separately repeated (3 h exposure time to antibodies/bovine serum albumin and 1 h 
agarose-capture). Finally, the pre-cleared lysate was collected and concentrated using the 
Vivaspin 500 centrifugal concentrator, 10 kD (GE Healthcare) for western blot analysis 
and kinase assays. 
Single cell capillary electrophoresis.  Custom made cell chambers were 
prepared by utilizing polydimethyl siloxane (PDMS, Sylgard 184) to glue a silicon O-
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ring to a glass coverslip (Fisher). The day before use, DU145 cells in suspension were 
diluted in 500 µL of complete media, plated on the chamber, and incubated in a 5% CO2 
humidified incubator at 37 ˚C. Single cell capillary electrophoresis was performed using a 
custom-made CE-LIF system, as described previously (Kottegoda et al., 2008; Proctor et 
al., 2012). Briefly, capillaries (30 µm inner diameter, 360 µm outer diameter, total length 
38 cm with an effective length 21.5 cm) were conditioned with 0.1 M NaOH for 12 h, 
distilled water for 1 h, 0.1 M HCl for 6 h and distilled water again for 12 h. To initiate 
electrophoresis, the inlet reservoir was held at ground and a voltage of -10 kV was 
applied to the outlet. The electrophoretic buffer was 300 mM Borate buffer at pH 7.5. 
Each new chamber of cells was first washed with a constant flow of extracellular buffer 
(ECB; 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM HEPES, pH 
7.4, 25 ˚C) for 4 min. Microinjection was performed using an Eppendorf Transjector 5246 
and InjectMan system. 114 µM peptide 1 and 90X phosphatase inhibitor cocktail mixture 
(diluted from 100X phosphatase inhibitor cocktail 2, Sigma-Aldrich) was microinjected 
into a single cell (200 hPa, 1 s). For cells not treated with Src inhibitor, the ECB flow was 
kept on until 20 s after the microinjection. For inhibitor-treated cells, the ECB flow was 
halted and replaced with 1 mL of inhibitor-containing ECB for 5 min. The ECB flow was 
turned on (40 s total) after microinjection to remove any residual peptides from the 
extracellular environment. The microinjected cell was incubated for 2 min prior to lysis 
by a focused Nd:YAG laser (Sims et al., 1998). The lysate from the single cell was 
immediately loaded into the capillary via electrokinetic injection and electrophoresed. 
Data was collected with custom software (LabVIEW 9.0.1, National Instruments) and 
analyzed by Origin (version 7.5, OriginLab Corporation). 
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Fluorescence microscopy.  Cells were plated on glass bottom dish the day before 
experiment and let adhere in a 37 ˚C, 5% CO2 humidified incubator.  The cells were 
washed with ECB buffer once before treated with cell permeable Src sensor 3 for 30 min 
at 37 ˚C. Peptide 3 stock solution (in anhydrous DMSO, stored at -80 ˚C) was diluted in 
ECB buffer to reach a final concentration of 5 µM. After removing peptide containing 
buffer, the cells were washed with ECB buffer again. Transmitted light images and 
fluorescein fluorescence images were taken using an inverted Olympus IX81 microscope 
with transmitted light and FITC filter cube.  
Matrigel invasion assay. Invasion assay was performed using BD BioCoatTM 
Tumor Invasion System. One key component of the tumor invasion system is the BD 
FluoroBlokTM insert, which contains polyethylene terephathalate (PET) membrane that 
blocks 490-700 nm light transmission. Therefore, fluorescence from cells in the top 
chamber is shielded from bottom-reading fluorescence plate readers and microscopes, 
whereas cells that invaded through the membrane to the bottom chamber can be easily 
detected without cell scraping and manual cell counting (BD Biosciences, 2010). The 
other key component is the BD MatrigelTM Matrix coating, which is a biologically active 
extracellular matrix preparation extracted from the Engelbreth-Holm-Swarm mouse 
sarcoma (BD Biosciences, 2008).  
The 24-multiwell tumor invasion system was warmed up to room temperature, 
and rehydrated with 500 µL serum free media (according to the cell line to be used) in a 
37 ˚C, 5% CO2 incubator for 2 h. The rehydrating media was then carefully removed 
without disturbing the Matrigel and the membranes. Prostate cells were grown in their 
complete media (as described in the Cell culture and cell lysate preparation section) to 
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~80% confluency in T75 flasks. The cells were washed with 10 mL DPBS, and lifted 
with 3 mL 0.53 mM EDTA, pH 8.0. Serum free medium (7 mL) was added to the 
detached cells, and centrifuge at 200 x g for 5 min to remove supernatant. The cells were 
then resuspended in serum free media containing 0.1% BSA. 500 µL cell solution 
containing 5 X 104 cells (counted using Scepter 2.0 handheld automated cell counter, 
Millipore) were added to the upper chamber of each well, and 750 µL complete medium 
(without antibiotics) was added to the lower chamber. The plate was then incubated at a 
37 ˚C, 5% CO2 incubator for 24 h. The cells were labeled with calcein 
acetoxymethylester (calcein AM, BD Biosciences), a non-fluorescent, cell-permeable dye 
that becomes fluorescent after being hydrolyzed in live cells. The PET membrane can 
block >99% of calcein fluorescence (Ex = 494 nm, Em = 517 nm) (BD Biosciences, 
2006). 100 µg calcein AM powder was first dissolved in 40 µL DMSO, then diluted in 20 
mL Hank's balanced salt solution (HBSS) to reach the final concentration of 5 µg/mL. 
The calcein AM solution was added to a new BD FalconTM 24 well plate at 500 µL/well. 
The upper chamber from the invasion system was taken out after incubation. The media 
was carefully removed and the chamber was transferred to the calcein AM containing 
plate. The cells in the upper chamber were labeled as well with 300 µL calcein AM 
solution. Labeling was allowed at 37 ˚C, 5% CO2 incubator for 1 h. The fluorescence 
reading from bottom and top was separately taken using a SpectraMax Gemini™ EM 
fluorescence plate reader at 494 nm excitation and 517 nm emission.  
Akt kinase assay using radiolabeled ATP.  Radiolabeled ATP kinase assays 
were performed with assistance from Dr. Lee Graves. 0.5 ng/µL active Akt1 kinase 
(S473D, Millipore 14-453) were spiked into assay solutions with a total volume of 20 µL. 
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Assay solutions contain: (1) Cell lysis buffer (CLB, 150 mM NaCl, 9.1 mM Na2HPO4, 
1.7 mM NaH2PO4, 1.0% nonidet P-40, 0.5% deoxycholic acid, pH 7.4) (2) kinase buffer 
(8 mM MOPS, 0.2 mM EDTA, 4 mM MgCl2), (3) RWPE1 cell lysate prepared in CLB, 
(4) RWPE1 cell lysate from (3) with addition of 46 mM β-glycerophosphate (BGP), and 
(5) RWPE1 cell lysate from (3) heat inactivated at 100 ˚C for 10 min. In addition, 10 mM 
MgCl2, 13.4 µM Akt substrate (peptide 6) or H2O for background controls were present 
in all assays. A mixture of 1 mM ATP and [γ-32P]ATP was used to initiate kinase 
reaction. The reaction mixtures were incubated for 30 min at 37 ˚C. Then the solution 
containing the substrate peptide was spotted onto phosphocellulose paper squares to 
capture the peptides. The papers were then washed in phosphoric acid extensively to 
remove unreacted [γ-32P]ATP. Liquid scintillation fluid (ScintiSafe Econo 2, Fish 
Scientific) was added to the dried papers, and the radioactivity was measured by a 
Multipurpose Scintillation Counter LS6500 (Beckman Coulter). 
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Results and Discussion 
The Src protein kinase is the founding member of the Src kinase subfamily of 
nonreceptor protein tyrosine kinases. The catalytic activity of these enzymes is regulated, 
in part, via phosphorylation (Roskoski, 2005). Specifically, full activation of Src is 
dependent upon phosphorylation at Tyr-416. By contrast, Tyr-527 phosphorylation 
inhibits catalytic activity, by promoting an intramolecular interaction with the enzyme’s 
SH2 (and SH3) domains. Indeed, the level of phosphorylated Tyr-527, as revealed by 
Western blot analysis, is often taken as a measure of inactive enzyme. However, this 
interpretation is fraught with danger. Although the low in vitro catalytic activity of pTyr-
527 Src is indisputable, the corresponding activity of the same enzyme in a biological 
environment is less certain. Upon interaction of the SH2 or SH3 domains of the Src 
enzyme with other proteins, the inhibitory pTyr-527 residue is released, which generates 
fully active pTyr-527 Src (Moarefi et al., 1997; Thomas et al., 1998; Zheng et al., 2000). 
Indeed, this process is recapitulated by short pTyr-containing peptides that, upon binding 
to Src’s SH2 domain, disrupt the intramolecular inhibitory pTyr-527 interaction and 
thereby activate kinase activity (Liu et al., 1993; Alonso et al., 1995; Boerner et al., 1996). 
Consequently, pTyr-527 status is not necessarily indicative of an inhibited enzyme per se, 
but rather of an enzyme that is potentially primed and ready to be “switched on” by 
interaction with an appropriate accessory protein. In short, high pTyr-527 Src levels 
could represent inhibited enzyme, activated enzyme, or some variant in-between. This 
uncertainty highlights the need to sample Src kinase directly via its ability to 
phosphorylate a target substrate.  
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 A variety of peptide-based substrates have been described to assay kinase activity. 
Generic ELISA- (Rijksen et al., 1996) and γ-32P-ATP-based (Braunwaler et al., 1996) 
methods are two of the most common, and very sensitive, strategies used for assessing 
activity with pure enzyme under in vitro conditions. In addition, fluorophore-labeled 
peptides (Wang and Lawrence, 2005; Wang et al., 2006b, 2006c, 2010b; Lawrence and 
Wang, 2007), as well as GFP-based proteins, have been described that exhibit a 
fluorescent response to phosphorylation, thereby allowing Src kinase activity to be 
continuously sampled in live cells via fluorescent microscopy (Ting et al., 2001; Wang et 
al., 2005). A biosensor that generates a fluorescent readout through binding to the “open” 
conformation of Src kinase has also been described (Gulyani et al., 2011). Although the 
latter technologies furnish a window into the biochemical basis of cell behavior, it is less 
readily translated into a routine and economical methodology for the rapid screening of 
the limited number of cells available in patient samples. 
 CE is an ultrasensitive method by which small amounts of analytes are separated 
and quantified, via the application of an electric field and subsequent detection of the 
analytes (Borland et al., 2008). The Src kinase catalyzes the transfer of the -phosphoryl 
group from ATP to the tyrosine residue of the substrate, which results in a change of the 
electrophoretic mobility. The latter enables separation of the starting nonphosphorylated 
peptide substrate from the final phosphorylated product (Li et al., 2001, 2004; Sims and 
Allbritton, 2003).  
Design and synthesis of the Src kinase sensor.  Based on the optimal Src 
substrate sequence identified from an oriented peptide library (Songyang et al., 1995), we 
developed the Src kinase substrate: 5-FAM-Orn(Ac)-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Phe-
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Orn(Ac)-amide (peptide 1), where Tyr represents the site of phosphorylation. Ornithine 
(Orn) residues were placed on each terminus of the peptide sequence, in the event that the 
peptide proved to display poor selectivity for Src versus other protein kinases. We have 
previously shown that side chain modification of active site-directed peptides with 
unnatural substituents can dramatically enhance the selectivity for the target protein 
kinase (vide infra) (Lee and Lawrence, 1999, 2000; Shen et al., 2001; Yeh et al., 2002a; 
Lee et al., 2004, 2008b; Li and Lawrence, 2005). Both the non-phosphorylated and the 
phosphorylated forms [5-FAM-Orn(Ac)-Glu-Glu-Glu-Ile-pTyr-Gly-Glu-Phe-Orn(Ac)-
amide (peptide 2)] of the peptide were prepared via solid-phase peptide synthesis. 5-FAM 
(5-carboxyfluorescein) was chosen as the fluorophore for substrate and product detection 
by laser-induced fluorescence (LIF).  
 The separation of the non-phosphorylated substrate and the phosphorylated 
product by CE-LIF is shown in Fig. 2.1. A 1:1 mixture of the peptides was loaded into 
the capillary. Under the separation conditions described in the Capillary electrophoresis 
section, the substrate peptide 1 emerges at 240 s, whereas the phosphorylated product 
peptide 2 appears at 290 s. Growth of the latter was monitored, as a function of time, by 
incubating peptide 1 with active Src kinase. The 290 s peak was confirmed to be the 
phosphorylated product by spiking with synthetic phospho-peptide (peptide 2). The 
kinetics of phosphorylation were obtained by evaluating collected time point samples via 
CE-LIF and quantifying the extent of phosphorylation via integration of the individual 
peaks. Src substrate phosphorylation is essentially complete within 3 min under the assay 
conditions used in these experiments that employed pure Src enzyme (Fig. 2.2). By 
contrast, subsequent experiments in cell lysates (vide infra) proceed at a more leisurely 
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pace. In the latter case, initial rate kinetics (<10% peptide phosphorylation) were acquired 
within 10 min of cell lysate incubation. (Fig. 2.3) 
           
Figure 2.1  CE-LIF separation and visualization of the Src peptide substrate 1 and 
its chemically synthesized phosphorylated counterpart 2. 
A 1:1 mixture of Src kinase substrate peptide 1 and its chemically synthesized 
phosphorylated counterpart peptide 2 was diluted in the CE running buffer (100 mM 
Borate/100 mM SDS buffer at pH 7.7) and hydrodynamically loaded into the capillary 
and separated at a constant voltage of 12 kV. The substrate peptide 1 emerges at 240 s, 
and the phosphorylated product peptide 2 appears at 290 s. (RFU = relative fluorescence 
units).   
R
FU
 
1 
2 
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Figure 2.2  Src kinase-catalyzed phosphorylation of the Src substrate as a function 
of time..  
Phosphorylation rate of Src substrate peptide 1 catalyzed by pure active Src kinase was 
assessed using the collected time point samples via CE-LIF. The extent of 
phosphorylation was quantified via integration of the individual peaks. All experiments 
were performed in triplicate. Error bars are showing SEM.  
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Figure 2.3  Phosphorylation kinetics of the Src substrate by prostate cell lysates. 
Phosphorylation rates were derived by plotting the fraction of peptide phosphorylated 
[phosphopeptide peak area/(phosophopeptide + unphosphorylated peptide area)] versus 
time. Assays were limited to less than 10% total peptide phosphorylation in order to 
insure that initial rate kinetics were obtained. 
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Stability of the Src kinase peptide substrate in prostate cell lysates.  Peptides 
commonly suffer protease-catalyzed degradation in cells as well as in cell lysates (Proctor 
et al., 2012). Consequently, prior to examining Src kinase-catalyzed phosphorylation of 
peptide 1 with lysates, we monitored the stability of the peptide as a function of time. 
Cells were lysed using Pierce’s M-PER mammalian cell lysis buffer and, in the absence 
of ATP and Mg2+ (i.e. no observable kinase activity), the lysate was added to Src 
substrate peptide 1. The stability of the peptide in the presence of lysate from the nine 
prostate cell lines is shown in Table 2.1. Only approximately 10% of the peptide is 
degraded after 1 h. Since the phosphorylation rate is measured within 10 min of 
incubation, the peptide is sufficiently stable for our needs.   
Cell Line % Remaining parent peptide 
PZ-HPV-7 92.4 ± 0.2 
RWPE1 91.0 ± 0.6 
WPE1-NA22 92.4 ± 0.8 
WPE1-NB14 91.4 ± 1.2 
WPE1-NB11 89.8 ± 1.5 
WPE1-NB26 91.0 ± 1.5 
22Rv1 91.2 ± 1.8 
DU145 92.9 ± 0.5 
PC3 89.2 ± 2.2 
 
Table 2.1  Stability of the Src peptide sensor in prostate cell lysates. 
Cells were lysed with M-PER protein extraction reagent without protease or phosphatase 
inhibitors. Approximately 90% of the parent peptide is still present, as assessed by CE, 
after 1 h incubation in the various cell lysates. Experiments were performed in triplicate. 
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Assessment of Src activity in prostate cell line lysates.  Tatarov et al. recently 
found a diminished survival rate in androgen-independent CaP patients with high levels 
of pTyr-416 Src (Tatarov et al., 2009). However, although pTyr-416 is necessary for Src 
kinase activity, it is not sufficient. As noted above, it is unclear what affect the presence 
or absence of a phosphorylated Tyr-527 residue has on Src activity given the possible 
existence of nearby protein binding partners. Src activity, as opposed to phosphorylation 
status, is a key point since recent preclinical and clinical studies have revealed that Src 
inhibitors, in particular dasatinib and saracatinib, hold significant promise for the 
treatment of CaP (Edwards, 2010). Both of these inhibitors target the ATP binding pocket 
of Src and therefore this form of therapy only makes sense for patients who actually 
display enhanced Src kinase activity. Consequently, we examined whether any 
correlation exists between total Src kinase activity and cell invasiveness using a series of 
prostate cell lines. 
 Our initial studies focused on the non-invasive immortalized normal prostate 
epithelial cell lines PZ-HPV-7 and RWPE1 and the highly invasive CaP cell lines DU145 
and PC3. We also investigated Src activity in the non-metastatic CWR22Rv1 cell line, 
which exhibits androgen-independent growth, a characteristic behavior of advanced stage 
CaP (Hsieh and Wu, 2009) correlated with the Src kinase (Tatarov et al., 2009).  
 Our studies assessed the initial rate kinetics (i.e. <10% of product formation) of 
peptide phosphorylation (Fig. 2.3). We found that Src kinase activity (as a function of 
total protein content) is high in the non-invasive cell lines (PZ-HVP-7 and RWPE1) and 
low in the invasive cell lines (DU145 and PC3) as well as in the cell line displaying 
androgen-independent growth (22Rv1) (Fig. 2.4). This general trend is at variance with 
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the general notion that high Src activity correlates with prostate cell line aggressiveness 
(i.e. invasive behavior and androgen-independent growth). Previous reports have noted 
that high levels of pTyr-416 are present in the most aggressive CaPs and it has been 
assumed, throughout the literature, that pTyr-416 and Src activity directly correlate with 
one another. One possible conclusion derived from our data is that the generally accepted 
notion that pTyr-416 levels serve as a barometer of Src activity is faulty. However, we 
investigated whether there might be alternative explanations for the unexpected 
relationship between Src activity and cell line invasiveness illustrated in Fig. 2.4. One 
possibility is that the Src substrate peptide 1 is phosphorylated by other protein tyrosine 
kinases thereby rendering the apparent inverse relationship between Src activity and cell 
invasiveness misleading.  
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Figure 2.4  Src kinase activities of PZ-HPV-7, RWPE1, CWR22Rv1, DU145 and 
PC3 prostate cell lines. 
Total Src kinase activities measured by CE-LIF in non-invasive (PZ-HPV-7, RWPE1), 
invasive (DU145, PC3), and androgen-independent (CWR22Rv1) prostate cell line 
lysates. Grey bars are phosphorylation rates of peptide 1 by whole cell lysates 
(normalized by total protein content). White bars are phosphorylation rates by cell lysates 
due to Src kinase alone after subtracting non-Src background phosphorylation of peptide 
1. All experiments were performed in triplicate. Error bars are showing SEM. The 1-
tailed t-test comparison values of Src kinase activity in noninvasive (PZ-HPV-7, RWPE1) 
versus invasive/androgen-independent (DU145, PC3, CWR22Rv1) cell lines is 0.0015. 
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Assessment of the selectivity of peptide 1 for Src in prostate cell lines.  We 
examined the Src-selectivity of peptide 1 using CaP cell lysates depleted of Src (Fig. 2.5). 
Although Src-free cell lysates are able to phosphorylate peptide 1, they do so to a much 
lesser extent (<20%) than with whole cell lysates containing Src. This is illustrated in Fig. 
2.4, where the white bars represent Src kinase activity in which background (i.e. non-Src) 
kinase activity has been subtracted out. The contaminating tyrosine kinases that may be 
responsible for the low level of Src substrate phosphorylation in the absence of Src could 
be one or more of the eight other members of the Src family kinases (SFK). Indeed, 
several SFK family members, such as Fyn, Brk, Lyn Lck and Yes are known to present in 
prostate cell lines (Chang et al., 2007). Nonetheless, given the relatively modest level of 
peptide 1 phosphorylation by Src-free lysates, we decided that peptide 1 is, for our 
present needs, sufficiently Src selective.   
 We also assessed the ability of the peptide 1/CE-LIF method to detect Src activity 
by using a combination of two known Src inhibitors. Imatinib (marketed as Gleevec), 
which is used to treat chronic myelogenous leukemia and other cancers, is an Abl-
selective inhibitor with demonstrated weak anti-Src activity. Imatinib blocks kinase 
activity by serving as a competitive inhibitor of ATP.  Like imatinib, saracatinib 
(AZD0530) is a competitive inhibitor of ATP, but displays a high selectivity and robust 
potency for Src. For example, the IC50 values of imatinib and saracatinib with isolated 
Src enzyme are 24.4 µM (Dar et al., 2008) and 2.7 nM (Green et al., 2009), respectively. 
Using DU145 cell lysates, we found that the potent Src inhibitor saracatinib blocks 
peptide 1 phosphorylation with a submicromolar IC50, whereas the correspondingly poor 
Src inhibitor imatinib displays an IC50 that is in excess of 100 µM (Fig. 2.6). These 
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results are consistent with the notion, exemplified by the Src depletion experiments that 
the peptide 1/CE-LIF method serves as an efficient and selective Src activity detection 
modality.  
 
 
Figure 2.5  Immunodepletion of Src kinase from prostate cell lysates. 
(A) Western blots of Src kinase in lysates with or without pre-clearance of Src. (B) The 
Src antibody used in immunodepletion displays no cross reactivity against other Src 
family kinases investigated. 2.4 µg of purified Src family tyrosine kinase member was 
loaded into each lane and exposed to the Src antibody employed in the immunodepletion 
experiment as well as other antibodies specifically against the Src kinase family members. 
A 
B 
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Figure 2.6  Src activity in DU145 lysates as a function of inhibitor concentration. 
Normalized Src activity (where 1.0 is defined as activity in the absence of inhibitor) in 
DU145 lysates as a function of log [inhibitor] (µM). (A) Where inhibitor = saracatinib 
(AZD0530) and (B) where inhibitor = imatinib (Gleevec). All experiments were 
performed in triplicate. Error bars are showing SEM.  
A 
B 
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Src expression levels in prostate cell lines.  Src activity is higher in non-
aggressive cell lines and lower in aggressive cell lines (Fig. 2.4), which appears to be 
inconsistent with the general notion that Src plays a key role in carcinogenesis, metastasis, 
and the transition to the androgen-independent state. However, it occurred to us that total 
Src content may vary from one cell line to the next, which could dramatically alter the 
apparent and surprising conclusion that Src activity and CaP aggressiveness display an 
inverse relationship. 
 Src content was quantified by western blot analysis (Fig. 2.7A) and normalized 
relative to α-tubulin (Fig. 2.7B). We found that the invasive cell lines, as well as the 
androgen-independent cell line, display less Src than the corresponding non-invasive, 
androgen-dependent cell lines. With the data from Fig. 2.7 in hand, we subsequently 
plotted “fractional Src activity” (i.e. total Src activity/total Src content) versus cell line 
“aggressiveness” (Fig. 2.8). The latter reveals a significant difference between fractional 
Src activity in normal versus aggressive (i.e. invasive or androgen-independent) cell lines 
(p = 0.0015).  
 Why is the total Src content greater in the PZ-HVP-7 and RWPE1 cell lines? One 
possible mechanism is the known sensitivity of activated Src, relative to its non-activated 
counterpart, to ubiquitin-mediated degradation (Hakak and Martin, 1999; Harris et al., 
1999). Consequently, cell lines that are under intense activated Src pressure might, 
ironically, display lower Src content than less aggressive cells. In addition, two recent 
studies suggest a second mechanism by which Src levels are regulated. Majid et al. 
reported that the micro RNA (miR) miR-205 downregulates the expression of Src at both 
the mRNA and protein levels, thereby inhibiting Src-mediated signaling pathways (Majid 
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et al., 2011). Interestingly, Bhatnagar et al. have shown that the more invasive the 
prostate cell line the higher the miR-205 level (Bhatnagar et al., 2010).   
  
 
Figure 2.7  Src protein levels in PZ-HVP-7, RWPE1, DU145, PC3 and CWR22Rv1 
prostate cell lines.  
(A) Prostate cell lysates were probed for total Src, where α-tubulin was used as the 
loading control. (B) Intensities of each band from the Western blots were measured and 
normalized to the corresponding α-tubulin control, and then compared to cell line 
RWPE1 (RWPE1 as 1). All experiments were performed in triplicate. Error bars are 
showing SEM.  
A 
B 
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Figure 2.8  Fractional Src kinase activity in PZ-HVP-7, RWPE1, DU145, PC3 and 
CWR22Rv1 prostate cell lines. 
Fractional Src kinase activity as assessed by measured Src activity (Fig. 2.4) divided total 
Src protein content (Fig. 2.7). All experiments were performed in triplicate. Error bars 
are showing SEM. The 1-tailed t-test comparison p-value of Src kinase activity in 
noninvasive (PZ-HPV-7, RWPE1) versus invasive/androgen-independent (DU145, PC3, 
CWR22Rv1) cell lines is 0.0015.  
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Src phosphorylation status in prostate cell lines.  Evans and colleagues recently 
reported that the Src inhibitor AZD0530 is most effective against prostate cell lines that 
have the highest ratio of active-to-total Src (Chang et al., 2008). In the latter study, 
“active Src” was taken to be pTyr-416 Src. These investigators also reported that cells 
with the lowest (pTyr-416 Src/total Src) ratios express the most Src. We also measured 
the levels of pTyr-416 via Western blot analysis and plotted pTyr-416 Src/total Src 
(fractional pTyr-416) versus cell line aggressiveness. As is evident from Fig. 2.9B, a 
relationship analogous to that depicted in Fig. 2.8 is apparent. These results allow us to 
conclude that pTyr-416 is a good indicator of catalytically active enzyme in prostate cell 
lines. Furthermore, the general observation that total Src content is lower in 
phenotypically aggressive prostate cell lines is consistent with the proteasomal and miR 
mechanisms described above. 
 We also examined what relationship, if any, exists between the level of pTyr-527 
Src and cell line aggressiveness. A plot of the ratio of pTyr-527 Src/total Src (fractional 
pTyr-527) (Fig. 2.9C) versus cell lines reveals a pattern similar to that in Figs. 2.8 and 
2.9B, namely aggressive cell lines display high “fractional Src activity” (Fig. 2.8), high 
fractional pTyr-416 content (Fig. 2.9B), and high fractional pTyr-527 content (Fig. 2.9C). 
Phosphorylation at Tyr-527 is considered to be inhibitory due to the formation of an 
intramolecular interaction that blocks Src kinase activity (Roskoski, 2005). However, as 
we’ve noted (vide infra), the pTyr-527 Src enzyme can be activated in the presence of 
phosphorylated peptides and proteins that disrupt the inhibitory interaction. In short, 
although pTyr-527 Src is inactive in purified form, the opposite appears to be true in cell 
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lysates. Consequently, we conclude that pTyr-527 Src levels are not a useful barometer of 
inactive Src and, rather, may actually be a more appropriate prognosticator of Src activity. 
A recent model of metastatic behavior known as “local excitation/global inhibition” 
poses the conjecture that aggressive tumor cells, relative to their non-aggressive 
counterparts, are able to generate highly localized bursts of signaling activity in response 
to growth factor gradients (Soon, 2007). However, our results suggest that a more apt 
description of aggressiveness may be the ability to globally recruit signaling enzymes to 
local pathways that drive the cancerous phenotype. This could have the consequence of 
depleting key enzymatic species from other pathways, a behavior that is consistent with 
the local excitation/global inhibition hypothesis. Under this scenario, the fraction of total 
potential signaling activity, as opposed to total activity alone, is a more meaningful 
measure of aggressiveness.  
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Figure 2.9  Phosphorylation status of Src in PZ-HVP-7, RWPE1, DU145, PC3 and 
CWR22Rv1 prostate cell lines.  
(A) Prostate cell lysates were probed for Src pY416 and pY527 levels, where α-tubulin 
was used as the loading control. (B) pY416 levels were derived from the band intensities 
in the Western blots, normalized to the corresponding α-tubulin control, and then 
compared to cell line RWPE1 (RWPE1 as 1). (C) pY527 levels were derived from the 
band intensities in the western blots, normalized to the corresponding α-tubulin control, 
and then compared to cell line RWPE1 (RWPE1 as 1). All experiments were performed 
in triplicate. Error bars are showing SEM.  
A 
B C 
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Src activity, expression and phosphorylation in prostate cancer progression 
model cell lines.  In addition to the standard prostate cell lines evaluated in Figs. 2.4 – 
2.9, we evaluated a series of N-methyl-N-nitrosourea cell lines derived from RWPE1. An 
advantage of these cell lines is that their relative invasiveness has been reported and 
displays the following order of increasing invasiveness: RWPE1, WPE1-NA22, WPE1-
NB14, WPE1-NB11 and WPE1-NB26 (Webber et al., 2001). In this series of cell lines, 
we observed correlations analogous to those described above for Src kinase activity and 
aggressiveness (with the exception of WPE1-NB26). First, as we noted in Fig. 2.4, total 
Src activity decreases as a function of increasing cell line aggressiveness (Fig. 2.10; grey 
bars). Second, once background tyrosine activity is subtracted out, it is evident that the 
majority of observed peptide phosphorylation is due to Src (Fig. 2.10; white bars). Third, 
total Src content decreases as a function of cell line aggressiveness (Fig. 2.11). Fourth, 
fractional Src kinase activity (Src kinase activity/total Src content) increases as a function 
of increasing cell line aggressiveness (Fig. 2.12). Finally, and somewhat surprisingly, the 
correlation between pTyr-416 fractional levels (pTyr-416/total Src content) and cell line 
aggressiveness is weak, suggesting that it may be dangerous to solely rely on pTyr-416 
content as a barometer of Src activity (Fig. 2.13A). However, we do observe a correlation, 
similar to that in Fig. 2.9C, with respect to fractional pTyr-527 content and cell line 
invasiveness (Fig. 2.13B). Curiously, one notable exception to the correlations observed 
for the WPE1 family is the NB26 line. The latter has received a significant amount of 
attention in the literature due to its highly aggressive behavior. Using total Src content 
and fractional Src activity as measures of aggressiveness, we would assign a non-invasive 
phenotype to WPE1-NB26 (i.e. similar to that of the parent cell line RWPE1). However, 
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since this is clearly incorrect, the invasiveness associated with this N-methyl-N-
nitrosourea cell line might due to mechanisms that are independent of Src signaling.  
 
Figure 2.10  Total Src kinase activity in prostate cancer progression model cell lines. 
Src-catalyzed phosphorylation rates in the RWPE1-derived cell lines WPE1-NA22, 
WPE1-NB14, WPE1-NB11, and WPE1-NB26 (increasing invasive ability as plotted 
along the x-axis). Grey bars are phosphorylation rates of Src sensor peptide 1 by whole 
cell lysates (normalized by total protein content). White bars are phosphorylation rates by 
cell lysates due to Src kinase alone after subtracting non-Src background phosphorylation 
of peptide 1.  
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Figure 2.11  Src expression levels in all prostate cell lines tested.  
(A) Prostate cell lysates were probed for total Src, pY416 Src and pY527 Src in all 
prostate cell lines tested, including the RWPE1-derived cell lines WPE1-NA22, WPE1-
NB14, WPE1-NB11, and WPE1-NB26 (increasing invasive ability as plotted along the x-
axis). α-tubulin was used as the loading control. (B) Intensities of total Src from the 
western blots for RWPE1-derived cell lines were measured and normalized to the 
corresponding α-tubulin control, and then compared to cell line RWPE1 (RWPE1 as 1). 
All experiments were performed in triplicate. Error bars are showing SEM.  
A 
B 
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Figure 2.12  Fractional Src activity in prostate cancer progression model cell lines.  
Fractional Src kinase activity was assessed by measured total Src activity (Fig. 2.10) 
divided total Src protein content (Fig. 2.11B).  
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Figure 2.13  Phosphorylation of Src in prostate cancer progression model cell lines. 
(A) pY416 levels of RWPE1-derived cell lines WPE1-NA22, WPE1-NB14, WPE1-
NB11, and WPE1-NB26 (increasing invasive ability as plotted along the x-axis) were 
derived from the band intensities in the western blots (Fig. 2.11A), normalized to the 
corresponding α-tubulin control, and then compared to cell line RWPE1 (RWPE1 as 1). 
(B) pY527 levels were derived from the band intensities in the western blots (Fig. 2.11A), 
normalized to the corresponding α-tubulin control, and then compared to cell line 
RWPE1 (RWPE1 as 1). All experiments were performed in triplicate. Error bars are 
showing SEM.   
A 
B 
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Assessment of cell line invasiveness.  We wanted to quantitatively compare the 
invasiveness of all nine cell lines and determine if we can correlate invasiveness with 
fractional Src activity or Src phosphorylation levels. As control, we used RWPE1, 
WPE1-NA22, WPE1-NB14 WPE1-NB11, WPE1-NB26 and DU145 cell lines where 
invasiveness was already quantified (Webber et al., 2001). To determine invasiveness we 
used the BD tumor invasion system that contains a fluorescent light blocking membrane 
and Matrigel, which mimics the basement membrane. The cells were labeled with cell 
permeable dye and the number of cells invaded through the Matrigel quantified by 
fluorescence (experimental details are described in Matrigel invasion assay section). 
The percentage of total cells invaded was used as a quantitative measurement of cell line 
invasiveness. As shown in Fig. 2.14, the invasiveness measured in our experiment has 
variance to what was published in the literature, especially for WPE1-NA22 and WPE1-
NB26 cell lines. We suspect that this is because the chemo-attractant used in our 
experiment is the standard cell culture medium, whereas in the previous studies, NIH/3T3 
cell conditioned medium was used, which contains a variety of growth factors that might 
not be present in the standard culture medium (Shaw, 2005), and therefore has a different 
effect on cell invasion. What is interesting to note is that the invasiveness measured in 
our experiment seems to correlate with the pTyr-416 level of Src in RWPE1 derived cell 
lines (Fig 2.13A). However, whether there is a direct relationship between pY416-Src 
and invasiveness requires further determination.  
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Figure 2.14  Invasiveness of prostate cell lines assessed by Matrigel invasion assay. 
Cell invasion assay was performed using BD Biocoat tumor invasion system. The cells 
were counted by fluorescence reading after calcein AM labeling. Invasiveness is 
presented by the percentage of total cells that have invaded through Matrigel to the 
bottom chamber. All experiments were performed in triplicate. Error bars are showing 
SEM.  
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Assessment of Src activity in single prostate cells.  An array of protein kinase 
assays has been described, including radioactive, colorimetric, and fluorescent methods 
(Braunwaler et al., 1996; Rijksen et al., 1996; Ting et al., 2001; Wang et al., 2005, 2006b, 
2006c, 2010b; Rothman et al., 2005; Wang and Lawrence, 2005; Lawrence and Wang, 
2007; Sharma et al., 2008; Li et al., 2008b; Uri et al., 2010; Newman et al., 2011). The 
majority of them are only appropriate for use with pure enzyme. However, a few 
fluorescent peptide- and GFP-based strategies have found applications in cell lysates and 
single cells (Wang et al., 2005; Gulyani et al., 2011). Unfortunately, the fluorescent 
changes displayed in single cells are typically modest, thereby requiring sophisticated and 
detailed one-cell-at-a-time microscopic inspection, including adjustments for 
photobleaching, assignment of the region of analysis, and adjustments for cell-to-cell 
differences in imaging parameters. By contrast, CE is not dependent upon a substrate-to-
product fluorescence change, nor does this extraordinarily sensitive method require labor-
intensive single cell analysis. As a consequence, CE can potentially be employed in an 
automated fashion, a significant advantage in a clinical setting where the operator’s level 
of expertise is not necessarily state-of-the-art. With these potential benefits in mind, we 
investigated whether the CE assay described in this study could be applied to single cells.   
 The Src substrate peptide 1 was microinjected into DU145 cells, incubated for 2 
min, each cell individually lysed with a focused Nd:YAG laser (Sims et al., 1998), the 
lysate immediately loaded onto the capillary via electrokinetic injection, and 
electrophoresed. In all DU145 samples containing peptide 1, the corresponding 
phosphopeptide (peptide 2) was observed (14 ± 2%). By contrast, no phosphorylation of 
peptide 1 was observed in DU145 cells pre-incubated with the potent Src inhibitor 
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AZD0530 (1 µM). An analogous set of studies were performed in the presence of 
imatinib (1 µM), a poor Src inhibitor. The level of phosphorylation (15 ± 3%) is 
essentially identical to that found in DU145 cells that had not been treated with inhibitor 
(Fig. 2.15). These studies confirm that evaluating Src activity at the single cell level is 
feasible and consistent with the experiments performed with lysates from large cell 
populations. 
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Figure 2.15  Single cell analysis of Src kinase activity in DU145 cells by CE.  
(A) Cells exposed to standard media, (B) standard media and imatinib (1 µM), and (C) 
standard media and AZD0530 (1 µM). All cells were subsequently microinjected with 
peptide 1, incubated for 2 min, lysed, injected into the capillary and electrophoresed. 
Electropherograms of (A), (B), and (C) are representative of results where n = 5 for each 
experiment. The small peak at 160 s is a component present in the media. Src substrate 
peptide 1 is the large peak observed approximately 100 s prior to that of the 
corresponding phosphopeptide. Control for (A): (D) lysate from cells exposed to standard 
media, microinjected with peptide 1 and incubated for 2min, then spiked with phospho 
standard peptide 2; control for (B): (E) lysate from cells exposed to standard media 
spiked with peptide 1 and peptide 2; control for (C): (F) lysate from cells exposed to 
standard media spiked with peptide 1 and peptide 2. Controls were run either 
immediately prior to or following the corresponding experiments in (A), (B), and (C). 
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Developing cell permeable Src sensor.  Although microinjection has proven 
successful in analyzing Src kinase activity in single cells, this technique is labor intensive 
and requires skilled practitioners. For routine diagnosis, a simple procedure that can be 
performed in a fast and automatic fashion is necessary. Therefore, we wanted to render 
the peptide kinase sensor cell permeable. Cellular delivery of peptides has always been a 
challenge for application of bioactive peptides for therapeutics and diagnosis. Many 
protein/peptide delivery reagents have been developed and are commercially available, 
such as Influx™ pinocytic cell-loading reagent (Invitrogen), Chariot™ protein delivery 
reagent (Active Motif) and BioPORTER® QuikEase™ protein delivery kit (Sigma 
Aldrich). However, the efficiency of these reagents is highly dependent on cell types and 
cargo properties. Moreover, materials from the delivery reagents are also introduced into 
cells, which might cause unwanted cellular responses. Peptide delivery has also been 
achieved by attaching long alkyl chains (Xie et al., 2003; Carrigan and Imperiali, 2005; 
Nelson et al., 2007). The disadvantages of this strategy are that additional amino acids 
need to be introduced into the peptide sequence for alkyl chain attachment, and the 
lipophilic alkyl chain is likely to raise problems in synthesis, purification and solubility.  
We have discovered a novel way of synthesizing cell permeabilizing peptides, as 
described in Chapter 3. This strategy, in which the N-terminal carboxyfluorescein (FAM) 
on Src sensor peptide 1 is replaced with carboxyfluorescein diacetate (CFDA), is 
particularly suitable for this project, since no additional moieties are introduced into the 
original peptide chain or to the cells. Cellular hydrolysis of CFDA will result in the 
original FAM labeled Src sensor (Scheme 2.1).  
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The CFDA labeled Src sensor peptide 3 was prepared by reacting the free N-
terminal amine containing peptide with CFDA-SE and purified by HPLC (details are 
described in Peptide synthesis section). Four prostate cell lines, DU145, PC3, RWPE1 
and WPE1-NB26, were tested for the cell permeability of peptide 3. As shown in Fig. 
2.16, after incubating with peptide 3 for 30 min, all cell lines exhibited green 
fluorescence signal, indicating uptake and hydrolysis of peptide 3. However, different 
fluorescence intensities were observed, which is probably due to varied uptake 
efficiencies by different cell types. To demonstrate that cellular uptake is facilitated by 
the CFDA moiety, the parent peptide 1 (labeled with FAM) was also incubated with the 
cells. As expected, none of the live cells showed fluorescence signals. These results, 
together with results from Chapter 3, indicate that labeling peptides with CFDA group 
could provide a new way of delivering peptides into cells, and at the same time, provide 
fluorescent molecules that can be used for fluorescent assays and microscopy studies. We 
do note that, however, in both studies punctate patterns were observed in cells. Additional 
studies are needed to identify and hopefully eliminate the punctate pattern. Moreover, 
optimization and more systematic studies are necessary to test the feasibility of this 
strategy for different peptide sequences and other cell types. 
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Scheme 2.1  The design of cell permeable Src sensor peptide 3. 
 
 
3 
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Figure 2.16  Uptake of peptide 3 by prostate cells. 
Prostate cell lines DU145, PC3, RWPE1 and WPE1-NB26 were incubated with 5 µM 
peptide 1 or peptide 3 in ECB buffer for 30 min. Transmitted light images and fluorescein 
fluorescence images were taken using an inverted Olympus IX81 microscope with 
transmitted light and FITC filter cube. 
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Simultaneous measurement of Src and Akt kinase activities.  Carcinogenesis, 
metastasis, and the transition to the androgen independent phenotype are all complex 
phenomena that are mediated by the interplay of a host of signaling pathways that are 
themselves driven by an array of protein kinases. Therefore, the ability to measure the 
catalytic activity of multiple protein kinases should be useful in this regard. In addition, 
the profiling of multiple protein kinases could prove helpful in cancer diagnosis as well 
as in the design of therapeutic strategies (Wang et al., 2010b). Indeed, several kinases, 
including Akt, S6K and Ack have been strongly implicated as potential markers for CaP. 
Given the extraordinary sensitivity and resolving power of CE, it should be feasible to 
simultaneously monitor an array of protein kinases.  
Akt is a serine/threonine kinase family that includes three closely related 
members, Akt1, Akt2 and Akt3 (also known as PKBα, PKBβ and PKBγ, respectively). 
Dysregulation of Akt expression and activation has been linked to many human diseases, 
including prostate cancer (Ayala et al., 2004; Li et al., 2005). Akt is activated via 
phosphorylation on two residues: serine 473 (S473) is located in a hydrophobic motif and 
is phosphorylated by the rictor-mTOR complex (Sarbassov et al., 2005); threonine 308 
(T308) is located in the activation loop and is phosphorylated by phosphoinositide-
dependent kinase 1 (PDK1) (Alessi et al., 1997).  Although S473 phosphorylation has 
been widely used to indicate Akt activity, studies by Vincent et al. have shown that 
pT308, but not pS473, correlates with Akt kinase activity in human non-small cell lung 
cancer (Vincent et al., 2011). Moreover, varied relationships exist between Akt activation 
status (phosphorylation level) and downstream substrate phosphorylation levels (Luo et 
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al., 2005). Therefore, an Akt activity sensor would prove useful in accurately assessing 
Akt activity and the relationship with prostate cancer progression.  
Proctor et al. have synthesized an Akt kinase sensor (peptide 4), 6FAM-
GRPRAATFAEG-amide (manuscript in preparation). As shown in Fig. 2.17, due to the 
difference in charge to mass ratio with the Src kinase sensor, both the Akt sensor (peptide 
4) and the synthetic phosphorylated counterpart (peptide 5) migrate differently on CE 
electropherogram than the Src sensor peptide 1 and peptide 2 under the same separation 
conditions (separation buffer: 100 mM Borate, 100 mM SDS at pH 7.4, separated at 25 
˚C using a constant voltage of 12 kV). Peptide 4 emerges at 380 s, peptide 5 emerges at 
180 s, whereas peptide 1 appears at 220 s and peptide 2 appears at 260 s. The non-
overlapping peak migration time allows us to investigate phosphorylation of peptide 1 
and peptide 4 simultaneously.  
                       
Figure 2.17  CE-LIF separation and visualization of Src sensor and Akt sensor. 
The Src kinase sensor (peptide 1, 220 s), phosphorylated counterpart (peptide 2, 260 s), 
Akt kinase sensor (peptide 4, 380 s) and phosphorylated counterpart (peptide 5, 180 s) 
were separated under the same CE conditions.  (RFU = relative fluorescence units) 
1 
2 
5 
4 
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Pure Akt1 (PKBα) kinase and Src kinase were employed to determine selectivity 
of peptide 1 and peptide 4 for these two enzymes. As shown in Fig. 2.18, Akt1 
selectively phosphorylated its substrate peptide 4, and Src selectively phosphorylated 
peptide 1. No cross-reactivity was observed. This is expected since Akt is a 
serine/threonine kinase whereas Src is a tyrosine kinase. It is interesting to note that when 
both Src and Akt kinases were present, the phosphorylation rate of Akt substrate was 
significantly faster than when only Akt kinase was present, indicating an elevation in Akt 
activity (Fig. 2.18C and D). We suspect that the Akt kinase (a recombinant human Akt1 
with S473D mutation expressed in Sf21 insect cells, purified and activated by PDK1, 
purchased from Millipore) is not in a fully active form, which contains unphosphorylated 
tyrosine residues, and when incubated with active Src in an ATP containing assay buffer, 
the tyrosine residues on Akt1 became phosphorylated by Src and results in elevated 
activity. Indeed, Src is known to phosphorylate tyrosine residues Tyr-315 and Tyr-326 on 
Akt both in vitro and in vivo and increase Akt activity (Chen et al., 2001a). Therefore, 
our results supported the model that Akt activity is not only regulated by serine/threonine 
phosphorylation, but by tyrosine phosphorylation as well.   
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Figure 2.18  Kinase-catalyzed phosphorylation of Src and Akt sensors as a function 
of time as assessed by CE-LIF. 
Red dots: Akt sensor peptide 4 phosphorylation; Black squares: Src sensor peptide 1 
phosphorylation. (A) Both peptide 1 and peptide 4 were incubated with Akt kinase, and 
only peptide 4 was phosphorylated. (B) Both peptide 1 and peptide 4 were incubated with 
Src kinase, and only Src substrate peptide 1 was phosphorylated. (C) Peptide 1 was 
incubated with Src kinase, peptide 4 was incubated with Akt kinase. Both sensors were 
phosphorylated by their kinase. (D) Both peptide 1 and peptide 4 were phosphorylated 
when incubated with Src kinase and Akt kinase together.  
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Measure of Akt activity in prostate cell lysates.  Akt activation (high S473 
phosphorylation level) has been shown to play an important role in the progression of 
prostate cancer to the androgen-independent state using prostate tumor cell lines (Ghosh 
et al., 2003). However, due to the complex relationship between Akt 
serine/threonine/tyrosine phosphorylation levels and enzymatic activity, we wanted to use 
the Akt sensor to directly measure Akt activity in prostate cells.  
Our initial study focused on aggressive prostate cancer cell lines DU145 and PC3. 
Constitutively active Akt is suggested in both cell lines, and the DU145 cell line is 
believed to contain higher amount of active Akt than PC3 cell line (Chen et al., 2001b).  
The cell lysates were prepared using M-PER protein extraction reagent and 5X Halt 
protease and phosphatase inhibitor cocktail. After incubating peptides 1 and 4 with either 
DU145 or PC3 cell lysates for 10 min, several peaks that correspond to peptidase 
degradation of peptide 4 appeared on the CE electropherogram and no (or very little) 
phosphorylation of peptide 4 was observed (Fig. 2.19). The fast degradation of peptide 4 
has been previously observed by Proctor et al. in HeLa cell lysates without protease 
inhibitors. However, even in the presence of high concentrations of protease inhibitors, 
degradation of peptide 4 can not be prevented in DU145 or PC3 cell lysates. To 
overcome the degradation issue, Proctor et al. have identified the peptidase cleavage sites 
on peptide 4 and designed a more stable Akt substrate by replacing cleavage site amino 
acids with cleavage resistant or unnatural amino acids. The new stable Akt kinase sensor 
(peptide 6), 6FAM-GRP-MeArg-AFTFAEG retained its substrate property. Therefore, 
we tested the stability and phosphorylation of peptide 6 in prostate cell lysate. However, 
although degradation peaks were successfully eliminated, no phosphorylation was 
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observed.  We suspect that Akt became quickly degraded or dephosphorylated when 
lysing the cells. Therefore, we tried several strategies: higher concentration (20X) of 
protease and phosphatase inhibitor cocktail, a different cell lysis buffer [1X RIPA buffer 
(Millipore) with 50 mM sodium fluoride, 40 mM β-glycerophosphate, 1 mM 
benzamidine and 0.5 mM phenylmethanesulfonyl fluoride, adapted from the studies by 
Bozinovski et al. (Bozinovski et al., 2002)], stimulation of PC3 cells with EGF or IGF-1, 
and different cell lines (293T, Jurkat) known to have activated Akt. Unfortunately, none 
of these methods generated cell lysate that can phosphorylate Akt substrate 6.  
With assistance from Dr. Lee Graves, we performed an Akt kinase assay using 
radio-labeled ATP. The results are shown in Fig. 2.20. The same concentration of active 
Akt1 kinase was spiked into (1) cell lysis buffer, (2) kinase buffer (80 mM MOPS, 2 mM 
EDTA, 40 mM MgCl2, pH 7.0), (3) cell lysate [RWPE1 cells lysed in cell lysis buffer in 
(1)], (4) cell lysate with high concentration of serine-threonine phosphatase inhibitor β-
glycerophosphate (BGP) or (5) cell lysate from (3) that has been heat inactivated for 10 
min. Interestingly, after incubating Akt substrate (peptide 6) with the active kinase 
spiked assay solutions, we observed different kinase activities. The highest Akt kinase 
activity was observed in the kinase buffer, whereas the cell lysis buffer inhibited Akt 
activity to nearly 50%. From these results, we suspect that some components in the cell 
lysis buffer inhibit Akt activity. There is almost no Akt activity in cell lysate, and even 
heat inactivation of the cell lysate did not prevent a reduction in Akt activity. Initially we 
suspect that Akt was dephosphorylated in cell lysate, therefore we used a high 
concentration of serine-threonine phosphatase inhibitor BGP to prevent the spiked active 
Akt from dephosphorylation. However, BGP seems to have a negative effect on Akt 
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activity. Furthermore, the inability to recover Akt activity from heat inactivated cell 
lysate suggests that there may be small molecules or short peptides in the cell lysate that 
inhibit Akt activity.  
 
Figure 2.19  Phosphorylation and degradation of Src and Akt sensors in cell lysates. 
(A) Peptide 4 and peptide 1 incubated in DU145 cell lysate for 1 min. (B) Peptide 4 and 
peptide 1 incubated in PC3 cell lysate for 1 min. (C) Peptide 4 and peptide 1 incubated in 
DU145 cell lysate for 10 min. (D) Peptide 4 and peptide 1 incubated in PC3 cell lysate 
for 10 min. Red arrow is where phosphorylated Src substrate (peptide 2) should appear. 
However, the peak is possibly overlaid with a degradation peak from peptide 4. Black 
arrow is where phosphorylated Akt sensor 5 should appear. The tiny peak in (D) is 
possibly peptide 5 or a degradation peak.  
A B 
C D 
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Figure 2.20  Radiolabeled ATP kinase assay. 
Akt activity was measured using radiolabeled ATP assay as described in the Akt kinase 
assay using radiolabeled ATP section.  
CPM = counts per minute 
BC-CPM = background corrected counts per minute 
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Simultaneous measurement of Src and EGFR kinase activities.  In addition to 
prostate cancer, Src kinase has also been implicated in tumor progression in other types 
of cancer. Src plays an important role in receptor tyrosine kinase (RTK) mediated 
signaling response by physically interacting with activated RTKs, serving both as a 
substrate and an activator to positively regulate RTK signaling (Guarino, 2009). One of 
the most widely studied RTKs is epidermal growth factor receptor (EGFR). 
Overexpression of EGFR has been indicated in ~60% cases of breast and other types of 
cancers, and correlates with poor patient outcomes. Studies have shown that 
overexpression of both EGFR and Src leads to enhanced cell migratory and invasive 
behavior (Dimri et al., 2007). Several small molecule inhibitors (e.g., gefitinib and 
erlotinib) that block EGFR enzymatic activity are currently under clinical trials. However, 
none of the inhibitors gave a complete response rate (Sheng and Liu, 2011). Indeed, 
cancer cell survival has been linked with the kinase-independent roles of EGFR (Weihua 
et al., 2008). Therefore, the ability to measure EGFR kinase activity, and determine the 
correlation between kinase activities and cancer progression will provide important 
information for both diagnosis and therapeutics.  
Phillips et al. have designed and synthesized an EGFR activity sensor (peptide 7), 
6FAM-EELEDDYEDDNleEE for CE analysis. They have demonstrated that peptide 7 is 
stable in cell lysate as well as in living cells, and can be efficiently phosphorylated in 
A431 cells, which contain a high level of EGFR activity. Because of the synergistic roles 
EGFR and Src play in cancer progression, we reasoned that it would be useful to 
simultaneously monitor Src and EGFR kinase activity in cancer cells. Because EGFR and 
Src are both tyrosine kinases and share some substrate similarities, we wanted to first 
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determine if the two kinase substrates (peptide 1 and 7) are selective for their targets. As 
shown in Fig. 2.21, both kinases are able to phosphorylate their substrate efficiently. 
However, when incubated with active EGFR kinase, Src substrate 1 is also quickly 
phosphorylated. Fortunately, no EGFR activity was detected by EGFR substrate 7 in 
prostate cell lines PZ-HPV-7, DU145 and PC3. However, we expect that the poor 
selectivity of peptide 1 between Src and EGFR will make it difficult to assess individual 
kinase activity in cancer cells with upregulated EGFR. Therefore, we decided to make a 
small library of Src kinase sensors and screen for a more selective Src substrate sequence.  
The library was designed based on the relative amino acid selectivity of Src and 
Lck kinase substrate and EGFR kinase substrate in a study published by Cantley and co-
workers. They showed that Src prefers hydrophobic amino acid Ile (I) or Val (V) at the 
Y-1 position, whereas EGFR prefers negatively charged Glu (E) or Asp (D) at this 
position. Both kinases prefer E or D at the Y-2 position, but Src can also accommodate 
Gly (G). At the Y+2 position, E is the preferred amino acid for both substrates, however, 
the Src kinase family member Lck can accommodate Val (V) (Songyang et al., 1995). 
Based on these findings, we rationally designed and synthesized peptides 9-14 (Table 
2.2). Phosphorylation of these peptides by EGFR or by Src kinase was examined and 
compared with peptide 1. We found that all the peptides (1 and 9-14) were 
phosphorylated at a similar rate by Src kinase. In contrast, peptides 9-14 exhibited a 
slower phosphorylation rate than peptide 1 when incubated with EGFR kinase. The lead 
compound from this library is peptide 14, which exhibits the highest selectivity for Src 
over EGFR. We have also examined the stability of peptide 14 in HeLa and A431 cell 
lysates prepared without any protease inhibitors, and no degradation peaks were observed.  
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Figure 2.21  Phosphorylation of Src sensor and EGFR sensor by Src or EGFR 
kinase. 
(A) Src sensor peptide 1 incubated with Src kinase for 1 h resulted in 93% 
phosphorylation. (B) EGFR sensor peptide 7 incubated with EGFR kinase for 1 h resulted 
in 59% phosphorylation. (C) Peptide 1 incubated with EGFR kinase for 1 h resulted in 44% 
phosphorylation. (D) Peptide 7 incubated with Src kinase for 1 h resulted in 8% 
phosphorylation. Peptide 1 (Src sensor) is the peak near 200 s; peptide 2 (phosphorylated 
Src sensor) is the peak near 240 s; peptide 7 is the peak near 375 s; the phosphorylated 
product (peptide 8) is the peak near 390 s.  
A B 
C D 
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 Peptide sequence 
Phosphorylation rate by 
EGFR kinase (pmol/min) 
1 5FAM-Orn(Ac)-E-E-E-I-Y-G-E-F-Orn(Ac)-amide 3.61 
9 5FAM-E-E-G-V-Y-G-E-F-amide 1.36 
10 5FAM-E-D-D-I-Y-G-E-F-amide 3.3 
11 5FAM-E-E-G-I-Y-G-E-F-amide 2.04 
12 5FAM-E-E-E-V-Y-G-E-F-amide 2.88 
13 5FAM-E-D-G-I-Y-G-E-F-amide 2.16 
14 5FAM-E-E-G-V-Y-G-V-F-amide 0.54 
 
Table 2.2  Peptide library for identifying selective Src substrate against EGFR. 
(A) Amino acid selectivity for Src, Lck and EGFR substrates.  
Reprinted from Songyang, Z., Carraway, K.L., Eck, M.J., Harrison, S.C., Feldman, R.A., 
Mohammadi, M., Schlessinger, J., Hubbard, S.R., Smith, D.P., Eng, C., et al. (1995). Catalytic 
specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536–539. © 
1995 Nature Publishing Group, used with permission.  
 
(B) A small library of peptides was designed and synthesized for screening for selective 
Src substrates against EGFR. The phosphorylation rate of each peptide by EGFR kinase 
was determined as described in the Protein kinase phosphorylation assay section. 
A 
B 
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Conclusions 
We have developed a sensitive and selective Src kinase activity sensing system. 
Using a series of prostate model cell lines, we have discovered that total Src activity 
decreases as a function of increasing prostate cell line aggressiveness. However, this 
unexpected (and ultimately misleading) observation is the consequence of a 
corresponding decrease in total Src content in the more aggressive cell lines. When the 
latter is taken into account (i.e. “fractional Src activity”), a positive correlation is 
observed between cellular aggressiveness and the fraction of cellular Src that is in the 
active state. In addition, we have found that pTyr-416 Src/total Src is a useful barometer 
of fractional Src activity for certain cell lines, although the correlation is suspect in the 
WPE1 cell line series. Furthermore, we found that the ratio of pTyr-527/total Src is a 
poor indicator of inactive Src but a good predictor of active Src.  
Cancer progression is the result of aberrant regulation of signaling networks 
driven by a variety of protein kinases. Our observation that increased “fractional Src 
kinase activity” correlates with aggressiveness may represent the ability of clinically 
aggressive cell lines to globally recruit signaling enzymes to local pathways that drive the 
cancerous phenotype. This conjecture will require additional data for verification, most 
notably using primary cells from clinical samples. In addition, the ability to profile 
multiple protein kinases that are implicated in cancer development could prove helpful in 
cancer diagnosis and therapeutics (Wang et al., 2010b). Given the high sample capacity 
of CE, it should be feasible to multiplex screens of kinase activity. We have demonstrated 
that Src and Akt sensors can be specifically phosphorylated by purified kinases and 
simultaneously monitored by CE-LIF. However, even though Akt kinase does not stay 
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active in a cell lysate, Proctor et al. have observed Akt-mediated sensor peptide 
phosphorylation in live LNCaP cells using single cell CE analysis. Therefore, it should 
prove feasible to simultaneously monitor Src and Akt kinase activity in live cells. 
Furthermore, we have improved the Src substrate for selective phosphorylation against 
EGFR. It would also be interesting to assess Src and EGFR activities in cancer cells, 
possibly in conjunction with Akt activity measurement as well. 
 
  
 
CHAPTER III 
UNRAVELING THE ROLES OF FYN AND LCK IN TCR SIGNALING  
BY A LIGHT-DEACTIVATABLE FYN KINASE INHIBITOR 
 
T-lymphocytes play key roles in the human immune system. T cells are activated 
by the interaction of the cell surface, multi-subunit T cell receptor (TCR) with an 
antigenic peptide on major histocompatibility complex (MHC) present on an antigen 
presenting cell (APC) (Nel, 2002; Sundberg et al., 2007). Following antigen recognition, 
T cell signaling pathways are activated, leading to changes in gene regulation and cell 
behavior. Proper induction of signaling pathways is crucial for the response to pathogens. 
Numerous diseases have been linked to aberrant activation of T cells (Wilkinson et al., 
2005; Datta and Milner, 2011; Wiegers et al., 2011).  
In the Src kinase family, FynT (the T cell isoform of Fyn) and Lck are the two 
members mainly expressed in T cells, and play a pivotal role in the initial signaling 
cascade upon TCR activation. FynT and Lck are believed to have distinct yet overlapping 
functionalities upon T cell stimulation (Zamoyska et al., 2003; Palacios and Weiss, 2004; 
Salmond et al., 2009). The differences in their specific roles can be attributed to the 
different localization of these two kinases in T cells. Lck is often found at the plasma 
membrane, whereas FynT usually localizes to the centrosome, and associate with 
microtubule cytoskeleton (Ley et al., 1994). Moreover, studies showed that FynT and Lck 
have different substrate specificities. Activated Lck phosphorylates ITAMs 
(immunoreceptor tyrosine-based activation motifs), leading to recruitment and activation 
85 
 
of ZAP-70 (zeta-chain-associated protein kinase 70), which subsequently induces the 
phosphorylation of T cell specific adapters, such as LAT (linker for activation of T cells) 
and SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa). Some studies showed 
that activated FynT kinase can specifically phosphorylate cytoskeletal regulators, such as 
WASP (Wiskott–Aldrich syndrome protein), FAK (focal adhesion kinase), and Pyk2 
(proline-rich tyrosine kinase 2) (Palacios and Weiss, 2004). However, controversial 
studies exist that indicate both Fyn and Lck can be responsible for phosphorylating some 
of the proteins mentioned above, such as ZAP-70, Pyk2 and LAT (Lovatt et al., 2006; 
Martín-Cófreces et al., 2006; Collins et al., 2010a, 2010b). Most studies aimed at 
unraveling the roles of Fyn and Lck were conducted by generating and using protein 
overexpressing, kinase deficient, or mutated cell lines. However, as Zamoyska et al. and 
Denny et al. have pointed out, stimulating responses in kinase-deficient or over-
expressed T cells seem to “mask rather than illuminate unique signaling niches” (Denny 
et al., 2000; Zamoyska et al., 2003). Therefore, the assumed specific or redundant 
functions by Fyn and Lck might have been mistaken simply as a consequence of 
experimental methods.  
Alternatively, using fast-acting, selective inhibitors to manipulate kinase activity 
in cells that contain normal protein levels should prove more useful in revealing the 
actual roles of the target kinase. Lck selective, cell permeable inhibitors have been 
developed in recent years, including synthetic small molecules (Meyn and Smithgall, 
2008; Won and Lee, 2008) and natural products (Faltynek et al., 1995). Imatinib 
(Gleevec), which is a potent Bcr-Abl inhibitor, has recently been found to be a selective 
inhibitor for Lck (IC50 = 2.6 µM), but not Fyn or Src (Lee et al., 2010b). Damnacanthal, 
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an anthraquinone derivative from plant extract, is a potent and selective Lck inhibitor 
[Lck (IC50 = 17 nM), ~20-fold selective for Lck versus Fyn] discovered by Michne and 
colleagues (Faltynek et al., 1995). However, the discovery and development of Fyn 
selective inhibitors has a much slower progress. To the best of our knowledge, the only 
reported selective inhibitor for Fyn versus Lck is a bivalent peptide developed by 
Lawrence and co-workers, that exhibits a 900-fold selectivity for Fyn (IC50 = 53 ± 4 nM) 
versus Lck (IC50 = 43 ± 4 µM) (Hah et al., 2006). However, applying bioactive peptides 
in cell signaling studies face the challenge of cellular delivery, and the ability of this 
peptide to penetrate a cell membrane has not been investigated. 
Furthermore, cellular response is often highly regulated in time and space. During 
TCR signaling, enzyme activation is turned on and off within several minutes. Kinases 
such as Pyk2 are known to have distinct phases of activation (Collins et al., 2010a). In 
such cases, the conventional inhibitors are limited by the fact that the biochemical 
contribution of their target kinases cannot be studied in a spatiotemporal fashion. Li et al. 
have developed a strategy to cage Src kinase by a potent light-deactivatable peptide 
inhibitor. This peptide contains three components: the N-terminus component targets Src 
kinase domain, the C-terminus component contains a pTyr-Glu-Glu-Ile-Glu sequence that 
binds to Src SH2 domain, and a photo-cleavable group containing linker connects the two 
components. The bivalent inhibitor has high inhibitory potency toward Src kinase, 
therefore Src activity is “caged” when binding to the intact peptide. Upon light-induced 
cleavage at the linker region, the inhibition was destroyed and thus restored up to 90% of 
Src kinase activity (Fig. 3.1) (Li et al., 2008a).  
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In this project, we explored the selectivity of photo-deactivatable peptide 
inhibitors between Fyn and Lck, and discovered a potent and highly selective Fyn 
inhibitor. Furthermore, we developed a new strategy to deliver the Fyn inhibitor peptide 
into Jurkat T cells. With this inhibitor, we should be able to selectively control Fyn 
kinase activity by light inside living T cells. We believe that this inhibitor will provide a 
powerful tool to study the complex roles played by Fyn and Lck in TCR signaling. 
 
 
 
 
Figure 3.1  A light-deactivatable Src family kinase inhibitor. 
Reprinted from Li, H., Hah, J.-M., and Lawrence, D.S. (2008). Light-mediated liberation of 
enzymatic activity: “small molecule” caged protein equivalents. Journal of the American Chemical 
Society 130, 10474–10475. © 2008 American Chemical Society 
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Materials and Methods 
Peptide synthesis.  3-methoxy-4-nitrobenzoic acid (Ba) and 1,4,5,6,7,7-
hexachloro-5-norbornene-2,3-dicarboxylic acid (Hna) were purchased from Sigma 
Aldrich. NovaSyn TGR resin, O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate  (HCTU), benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBop), N-hydroxybenzotriazole 
(HOBT), Fmoc-e-Ahx-OH, Fmoc-Tyr(PO(OBzl)OH)-OH,  Fmoc-β-Ala-OH and other 
common Fmoc protected amino acids  were purchased from NovaBiochem. Fmoc-
Dap(Aloc)-OH and 3-Nα-Fmoc-amino-3-(2-nitrophenyl)propionic acid (ANP linker) 
were obtained from Advanced ChemTech. (5,6)-carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE) was obtained from AnaSpec. Tetrakis 
(triphenylphosphine) palladium (Pd(PPh3)4) was purchased from Strem Chemicals. Other 
common chemicals such as N,N-dimethylformamide (DMF), dichloromethane (DCM), 
N,N-diisopropylethylamine (DIPEA),  triisopropylsilane (TIS), N-methylmorpholine 
(NMM) and trifluoroacetic acid (TFA) were obtained from Sigma Aldrich or Fisher 
Scientific. 
Ba-E(OtBu)-E(OtBu)-E(OtBu)-I-F-G-E(OtBu)-F-Dap(Aloc)-C(trt)-ANP-βA-
pY(OBzl)-E(OtBu)-E(OtBu)-I-E(OtBu)-Ahx-K(Boc)-CONH2 was synthesized on the 
NovaSyn TGR resin (0.2 mmol/g, 1 g resin, 0.2 mmol scale) using a standard peptide 
coupling protocol on a Protein Technology International Prelude peptide synthesizer. 
Briefly, TGR resin was mixed with amino acid (5 equiv/equiv resin), HCTU (5 
equiv/equiv resin) and DIPEA (12 equiv/equiv resin) in DMF and reacted for 10 min at 
room temperature. Fmoc was deprotected by 20% piperidine in DMF for 20 min at room 
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temperature. Ba moiety was coupled to the free N-terminus at the end of the reaction. The 
subsequent processes were done manually. The allyloxycarbonyl (Aloc) group on the 
Dap residue was removed by mixing Pd(PPh3)4 (3 equiv) and CHCl3/AcOH/NMM 
(37:2:1, 15mL/g of resin) with the peptide for 3 h.  Hna moiety was then coupled via 
exposure of Dap side-chain free amine to 50 equiv Hna, 50 equiv PyBop and 250 equiv 
NMM in DMF for 3 h. The peptide was cleaved from the resin using TFA/TIS/H2O 
(95:2.5:2.5) along with side chain deprotections.  
Peptide 26 was prepared by reacting purified peptide 25 with CFDA-SE. HPLC 
purified and lyophilized peptide 25 was weighed and dissolved in 1X PBS (pH 7.4) 
buffer (10 mg peptide/3mL PBS). CFDA-SE (1.5 equiv/equiv peptide) was dissolved in 
anhydrous DMSO and then slowly added into peptide solution to react for 1.5-3 h. 
Peptide 27 was prepared by reacting peptide 25 with (5)-FAM-SE. 1 equiv of purified 
peptide 25 was dissolved in 0.1 M NaHCO3, pH 8.4 buffer (~1 mg peptide/1 mL buffer). 
1.5 equiv (5)-FAM-SE powder was dissolved in anhydrous DMSO, and slowly added to 
peptide 25 solution to react for 2-3 h. 
Peptides 25, 26 and 27 were purified by a preparative C18 column on HPLC 
(Waters) using a binary solvent system, and confirmed by ESI-MS. C123H159Cl6N24O46PS 
(peptide 25) calculated Mass: 2985.47, found 2985.0; C148H173Cl6N24O54PS (peptide 26) 
calculated Mass: 3427.84, found 3426.6; C144H169Cl6N24O52PS (peptide 27) calculated 
Mass: 3343.77, found 3343.5. 
IC50 Measurement.  Active Src family kinases were purchased from Invitrogen 
(Src: P3044, Fyn: P3042, Lck: P3043, Blk: PV3683). Other commonly used reagents 
were purchased from Fisher Scientific or Sigma Aldrich. IC50 values of all bivalent 
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inhibitors were determined as previously reported (Hah et al., 2006). Specifically, 
reaction was initiated by addition of 5 μL of 10 mM ATP to the following solution: 5 μL 
of various concentrations of inhibitor, 0.25 μL 2 mM fluorescent peptide substrate, 1.26 
μL 200 mM MgCl2, 0.25 μL 200 mM MnCl2, 2 μL 50 mM DTT, 1 μL 0.5 mg/mL BSA, 
2 μL 0.26 μM Src family kinase, 8 μL H2O and 25.2 μL 100 mM Tris buffer solution (pH 
7.5). The final concentration was: 10 μM peptide substrate, 10 nM Src family kinase, 1 
mM ATP, 50 mM Tris at pH 7.5, 5 mM MgCl2 1 mM MnCl2, 0.01 mg/mL BSA, 2 mM 
DTT. The fluorescent peptide substrate used in this assay gives a phosphorylation 
dependent change (~4-fold) in pyrene fluorescence intensity (Wang et al., 2006b). The 
fluorescence was monitored by bottom reading from a clear bottom multi-well plate on 
Molecular Devices SpectraMAX Gemini EM fluorescence plate reader at 37 ºC 
(excitation wavelength is 343 nm and emission wavelength is 380 nm). Reaction rates 
were measured within 10% product formation. Fractional velocities (v/v0) were plotted 
against inhibitor concentrations and data was fitted to a full-4 parameter equation to 
calculate IC50 (Grafit5 software).  
 
Range: the maximum y range.  
s: slope factor.  
x: the analyte concentration . 
Fluorescence microscopy.  Uncoated glass bottom dishes (35 mm, glass No. 1.5) 
were obtained from MatTek Corporation. To facilitate adherence of Jurkat E6-1 cells, the 
plates were coated with gelatin by adding 200 µL of 2% gelatin to the glass surface and 
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incubated at 37 ºC for 30 min, followed by washing with DPBS three times. Poly-d-
lysine coated glass bottom dishes (MatTek) have also been used to adhere cells. For time-
dependent uptake experiments, Jurkat cells were first pelleted at 400 x g for 5 min and 
washed with DPBS, then resuspended in 500 µL of DPBS and added to gelatin coated 
dishes. After letting cells adhere for 10 min at room temperature (RT), 10 µM final 
concentration of peptide 26 was added to the dish. Live cell time-course fluorescence 
images (Fig. 3.2A) were taken using a Zeiss 510 Meta laser scanning confocal 
microscope with a 488 nm argon laser and a 63x oil objective at UNC Michael Hooker 
microscopy facility.  
For the fixed time-point experiment, the cells were first pelleted and washed with 
DPBS (X3), then incubated with 10 µM peptide 26 for 30 min. After washing the treated 
cells once again in DPBS buffer, the cells were plated on poly-d-lysine coated plates and 
let adhere for about 5 min. The fluorescence image (Fig. 3.2B) was taken using an 
Olympus IX81 inverted wide-field microscope equipped with a Hamamatsu C8484 
camera, a xenon arc lamp, a 60x oil objective and a FITC filter cube. 
The trypan blue staining was performed by incubating 10 µM peptide 26 pre-
treated Jurkat cells with 0.2% trypan blue (Sigma Aldrich) for 2 min and then diluted in 
PBS buffer before imaging. The images (Fig. 3.2C) were taken using an Olympus IX81-
ZDC inverted fluorescence microscope equipped with a QImaging RETIGA 4000R color 
camera, an Hg Arc lamp, a 40x objective and a FITC filter cube at UNC-CH Lineberger 
Microscopy Services Laboratory. 
Affinity pull-down assay. Peptide 25 affinity pull-down column was prepared 
according to manufacturer’s instruction using Affigel-15 resin purchased from Bio-Rad. 
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Specifically, 600 µL of uniformly suspended Affigel-15 resin was added to the column, 
washed with 3-5 mL of ice-cold isopropyl alcohol (IPA), and centrifuge at 1000 x g for 1 
min to remove all solvent. Purified and lyophilized peptide 25 was dissolved in 200 µL 
anhydrous DMF and added to the resin. The reaction was carried out by adding 300 µL 
additional anhydrous DMF and 5 µL DIPEA to the resin and rotated at RT for 4 h. The 
resin was then washed with 5-10 mL ice-cold IPA. The unreacted N-hydroxysuccinimide 
(NHS) ester was blocked by reacting with 200 µL of ethanolamine for 1 h at RT. The 
affinity column was stored in IPA or PBS buffer at 4 ºC.  
Before use, the column was washed with 500 µL PBS buffer 10 times. Native cell 
lysates were added to the resin and rotated for 5-7 h at 4 ºC. The flow through was 
collected by spinning the column at 1000 x g for 1 min and washed with flow through 
buffer (5 mM MgCl2, 1 mM MnCl2, 2 mM DTT, 10 µg/mL BSA, 1 mM ATP in 100 mM 
Tris HCl pH 7.5 buffer) 6 times. The flow through was condensed using a Vivaspin 6 (10 
kD) concentrator. The Affigel-peptide bound proteins were eluted by boiling in 1X SDS 
loading buffer (50 mM Tris HCl pH 6.8, 100 mM DTT, 20% SDS and 12.5% glycerol) 
for 10 min.  
Native cell lysate preparation and total protein concentration measurement.  
Jurkat E6-1 cells were pelleted at 1000 x g for 2 min, and washed with 5 ml of ice-cold 
DPBS twice. M-PER mammalian protein extraction reagent with 1X Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific) was added to the cells and mixed at 
4 °C for 10 min. Cell debris was removed by centrifuging samples at 16,000 x g for 10 
min at 4 °C. The total protein concentrations were determined by comparing to known 
concentrations of BSA using Dc Protein assay (Bio-Rad). 
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T cell growth and stimulation.  Jurkat E6-1 cells were obtained from ATCC, 
cultured and stimulated essentially as described before (Collins et al., 2010b). In brief, 
the cells were cultured in RPMI1640 medium (Cellgro) supplemented with 10% FBS 
(Omega Scientific) and 1% penicillin/streptomycin (Cellgro) at a 37°C, 5% CO2 
humidified incubator. For Fyn inhibitor treatment, cells were grown to a concentration of 
2–5 X 105 cells/mL (counted by Scepter™ 2.0 Cell Counter, Millipore), collected and 
washed in DPBS (GIBCO) for 3 times. Then resuspended to 5-6 X 107 cells/mL in DPBS 
and incubated for 10 min at 37°C. The cells were treated with different concentrations of 
peptide 26 (stock solutions in DMSO were diluted 100X in cell containing PBS) for 10 
min at 37°C. For Lck inhibitor damnacanthal (EMD chemicals) treatment, cells were 
washed and resuspended in RPMI1640 medium without supplement and incubated for 10 
min at 37°C. The cells were then treated with different concentrations of Lck inhibitors 
(stock solutions in DMSO were diluted 100X in cell containing PBS) for 4 h in a 37°C, 5% 
CO2 humidified incubator.  
Without washing, the cells were stimulated with 10 µg/mL anti-CD3 antibody 
[OKT3] (Abcam, ab86883) for 1 min at 37°C. Stimulation was stopped by lysing cells 
with a 4 fold excess (v/v) of 95°C denaturing lysis buffer (20 mM Tris pH 8.0, 2 mM 
EDTA, 2 mM Na3VO4, 20 mM DTT, 2% SDS and 20% glycerol). The lysates were kept 
at 95°C for 4 min and then sonicated briefly using Fisher Scientific model 50 sonic 
dismembrator (10 amplitude, 5-10 s) to reduce viscosity. 
Western blot experiments.  Primary antibodies phospho-Pyk2 (Tyr402) and 
phospho-Pyk2 (Tyr580) were purchased from Invitrogen; phospho-LAT (Tyr191) was 
purchased from Cell Signaling Technology; β-actin antibody was purchased from Sigma 
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Aldrich (A5441); Fyn antibody and Lck antibody were obtained from BD Biosciences. 
Secondary antibodies (Amersham ECL anti-rabbit/mouse IgG HRP linked species-
specific whole antibody from donkey) were purchased from GE healthcare. 20X TBS 
buffer was obtained from AMRESCO. Ultrapure Tris, glycine and SDS were obtained 
from Invitrogen. Methanol was obtained from Fisher Scientific.  
In affinity pull-down experiment, proteins were separated using NuPage 4-12% 
Bis-Tris gel (Invitrogen), running at 200 V for 60 min. Gels were then transferred to 
PVDF membranes using iBlot dry blotting system (Invitrogen). Blocking, antibody 
incubation, and washes were performed on SNAPid (Millipore). Specifically, the 
membranes were first blocked using 0.5% non-fat milk in PBST (1X PBS with 0.1% 
Tween-20) buffer for 1 min. After removing the blocking buffer, the membranes were 
incubated with primary antibodies (Fyn antibody was diluted 1:250; Lck antibody was 
diluted 1:1000 in blocking buffer) for 15 min (X2). The membranes were then washed 
with PBST for 3 times. Then secondary antibodies (1:400 dilution in blocking buffer for 
Fyn; 1:1000 dilution for Lck) were applied for 15 min. The membranes were 
subsequently washed with PBST (X3), 0.5% NaCl (X3) and PBS (X3). The blots were 
detected by Amersham ECL Plus (GE Healthcare) and the chemiluminescence images 
were obtained by the FluoChemFC2 system (Alpha Innotech).  
In experiments detecting Pyk2 and LAT proteins, cell lysates were separated 
using Novex 4–20% Tris-Glycine pre-cast gel in Novex Tris-Glycine SDS buffer 
(Invitrogen) at 125 V for 2 h. The proteins were then transferred to PVDF membrane 
(Invitrogen) using transfer buffer (25 mM Tris, 190 mM glycine, 0.1% SDS and 20% 
methanol), 120 mA constant current at 4°C overnight. To analyze site-specific 
95 
 
phosphorylation, the membranes were blocked for 1 h at RT in a blocking buffer 
consisting of TBST (1X TBS with 0.1% Tween-20) with 5% nonfat dry milk (Santa Cruz 
Biotechnology). The membranes were then washed in TBST for 5 min (X3). Primary 
antibodies were diluted 1:1000 (1:3000 for β-actin antibody) in TBST containing 5% 
BSA (Sigma) and then incubated with the membrane at 4°C overnight. After washing 
with TBST for 5 min (X3), the membranes were incubated with the secondary antibody 
(1:1000 diluted in blocking buffer) at RT for 1 h, followed by washing in TBST for 10 
min (X3). Antibody binding was identified with Amersham ECL Plus (GE Healthcare) 
and the chemiluminescence images were obtained by the FluoChemFC2 system (Alpha 
Innotech). The densitometry analysis of the bands was performed using the AlphaView 
software. Three independent replicates were performed for each experiment. To perform 
the loading control, all membranes were stripped for 20 min at RT using Restore plus 
Western blot stripping buffer (Pierce), washed in TBS for 5 min (X3), and reprobed for 
β-actin. 
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Results and Discussion 
Determination of IC50 and selectivity of light-deactivatable peptide inhibitors 
for Fyn and Lck.  Src kinase family members share highly homologous domain 
structures. However, specific differences exist in the linker region between the SH1 and 
SH2 domain. These differences correlate with the subgrouping of Src family kinases 
(SFKs) (Group A: Src, Yes, Fgr, Yrk and Fyn; Group B: Blk, Lck, Hck and Lyn) 
(Williams et al., 1998). Moreover, studies by Miller et al. suggest that the relative 
positioning of SH1 domain to SH2 domain is important for proper substrate recognition 
(Yadav and Miller, 2008). A highly potent “group A” selective Src kinase inhibitor has 
been developed based on the spatial orientation of the SH1-SH2 domain. This inhibitor 
contains SH1- and SH2-directed components linked by a three β-Ala tether. The tether 
length between the two components is believed to be critical for inhibitor potency and 
selectivity (Hah et al., 2006). Based on this “group A” selective inhibitor, Li et al. have 
prepared a small library of photo-cleavable peptide inhibitors by changing the three β-Ala 
tether into a photo-labile moiety containing linker. Several potent inhibitors for Src 
kinase have been identified from this library (Li et al., 2008a). However, the selectivity of 
these photo-cleavable inhibitors between “group A” and “group B” of Src family 
members has not been examined. Although these inhibitors were designed based on the 
“group A” selective peptide sequence, the linker region has been changed to contain a 
photo-cleavable moiety, which might affect the inhibitor potency and selectivity. 
Therefore, we tested the IC50 and selectivity of this small library of photo-cleavable 
peptides towards four Src family members: Src, Fyn, Lck and Blk. 
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As shown in Table 3.1, IC50 values of these peptides are similar for Src and Fyn, 
which is expected since Fyn and Src are both members of the “group A” SFKs. In 
contrast, these peptides are poorer inhibitors for Lck and Blk (“group B” SFKs), and 
exhibit different selectivity between Fyn and Lck. The control peptide 16 [Fyn (IC50 = 
1.34 µM), Lck (IC50 = 26.7 ± 0.5 µM)] is a 1:1 mixture of the two components of the 
bivalent inhibitor, which is used to mimic the resulting compounds after light induced 
cleavage. Among these inhibitors, we have identified a lead compound peptide 24 [Src 
(IC50 = 0.056 ± 4 µM); Fyn (IC50 = 0.025 ± 0.003 µM); Lck (IC50 = 13.6 ± 1.4 µM); Blk 
(IC50 = 2.29 ± 0.42 µM)]. Although peptide 24 is not able to discriminate within “group 
A” (Src and Fyn) or “group B” (Lck and Blk), the 543-fold selectivity for Fyn versus Lck 
should prove sufficient to study signaling mechanisms of these two kinases in T cells.
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# *Peptide Src IC50 (nM) 
Fyn IC50 
(nM) 
Lck IC50 
(nM) 
Blk IC50 
(nM) 
Lck/Fyn 
15 Ba-EEEIFGEF-Dap(Hna)-βA3-pYEEEIEX 21±1.5 16±1.6 2250±140 5100±160 141 
16 Ba-EEEIFGEF-Dap(Hna)X + AcpYEEIE-NH2 627±48 1340 26700±510 4860±2120 20 
17 Ba-EEEIFGEF-Dap(Hna)-βA-I-βA-pYEEIEX 48±4 88±15 4960±600 2920±260 56 
18 Ba-EEEIFGEF-Dap(Hna)-βA-II-βA-pYEEIEX 12±1 51±12 8450±4000 2950±370 166 
19 Ba-EEEIFGEF-Dap(Hna)-βA-III-βA-pYEEIEX 6.6±0.4 15±0.8 1560±100 2930±550 104 
20 Ba-EEEIFGE-II-Dap(Hna)-βA3-pYEEEIEX 632±113 350±34 >59000 8550±2530 171 
21 Ba-EEEI-III-GEF-Dap(Hna)-βA3-pY-III-EIEX >56000 >37000 >56000 >43000 NA 
22 Ba-EEEIFGE-III-Dap(Hna)-βA3-pY-III-EIEX 12800 16000 >19000 4400±2760 NA 
23 
Ba-EEEIFGEF-Dap(Hna)-βA-III-βA-pY-III-
EIEX 
211±86 360±48 >12000 3770±3400 NA 
24 Ba-EEEIFGEF-Dap(Hna)C-III-βA-pYEEIE-NH2 74±7 25±3 
13600±140
0 
2290±420 543 
 
                      
*
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Table 3.1  IC50 and selectivity of peptide inhibitors for Src, Fyn, Lck and Blk.  
The * labeled peptide sequences and the compound structures were adapted from the 
previously published paper: 
Li, H., Hah, J.-M., and Lawrence, D.S. (2008). Light-mediated liberation of enzymatic activity: 
“small molecule” caged protein equivalents. Journal of the American Chemical Society 130, 
10474–10475. © 2008 American Chemical Society, used with permission. 
 
The IC50 measurements of peptide 15-24 for Src kinase were repeated in this study, and 
showed comparable results with previously published data. IC50 values for Fyn, Lck and 
Blk kinases were measured, and the selectivity between Fyn and Lck was compared.  
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Cellular delivery of the Fyn selective inhibitor.  One of the challenges to 
applying bioactive peptide reagents is cellular delivery. Many techniques have been used 
to introduce cell impermeable proteins and peptides into intact cells, including 
microinjection, electroporation, osmotic lysis of pinosomes, liposome mediated delivery 
and red blood cell ghost fusion. These techniques have their advantages and 
disadvantages. For example, microinjection allows precise control over delivering 
concentration and timing, but is only appropriate for single cell analysis (Zhang and Yu, 
2008a, 2008b). The osmotic lysis of pinosomes utilizes a hypertonic reagent to allow 
molecules carried into cells via pinosomes, which was later released into cytosol by 
changing to hypotonic solution. However, osmotic treatment can cause unwanted changes 
in cell signaling and behavior (Okada and Rechsteiner, 1982; Chakrabarti et al., 1989). 
Permeabilizing peptides can also be achieved by attaching cell penetrating peptides (CPP) 
(Stewart et al., 2008) or fatty alkyl chains (Toth, 1994) via disulfide bond. However, the 
Fyn selective inhibitor 24 is a heavily modified peptide, thus we would anticipate 
encountering synthesis, purification and solubility difficulties if using these methods. 
Moreover, the efficiency of CPP- or fatty alkyl chain-mediated delivery is largely 
dependent on the cell type and cargo properties (Maiolo et al., 2005). Nelson et al. have 
shown that cell penetrating peptide TAT failed to deliver an Abl peptide inhibitor into 
Jurkat T cells, whereas HeLa cells can be readily loaded under similar conditions (Nelson 
et al., 2007). 
Unsatisfied with the current cell delivering methods, we wanted to screen a 
compound library aiming to identify a novel cellular delivery agent for the Fyn inhibitor 
peptide. In order to monitor the uptake of peptide 24 by cells, we prepared a 
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profluorescent peptide 26 (synthesis is shown in Scheme. 3.1). A short Ahx-Lys spacer 
was added to the C-terminus of the parent peptide 24 to reduce interference of the 
fluorophore to peptide binding affinity for Fyn, and also provide a lysine side-chain 
amine for fluorophore conjugation (peptide 25). A profluorescent carboxyfluorescein 
diacetate (CFDA) moiety was used so that only those taken up by cells will be 
fluorescent upon intracellular hydrolysis of the diacetate groups. This uptake-and-report 
design eliminates the washing steps and therefore is more feasible for high-throughput 
screening (especially when non-adherent T cells are used). Moreover, after intracellular 
hydrolysis of CFDA, the resulting carboxyfluorescein (FAM) is not cell permeable, 
which should help to retain the peptide inside cells (Scheme 3.2). 
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Scheme 3.1  Synthesis of the profluorescent peptide 26.  
  
25 
26 
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Scheme 3.2  The “uptake and report” design of peptide 26. 
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Surprisingly, live cell images revealed that the CFDA labeled peptide 26, without 
any additives, efficiently penetrated Jurkat E6-1 cells within 10 min. As shown in Fig. 
3.2A, Jurkat T cells clearly show an increase in green fluorescence signal as a function of 
incubation time, indicating uptake and accumulation of the peptide inside cells. We 
suspect that since the parent peptide 24 is heavily negatively charged, it is not likely to be 
able to penetrate cells. Therefore, the cell permeable profluorescent moiety CFDA may 
be the key for delivering the entire molecule into cells. However, we do note that 
punctate-endosome like structures were observed in Jurkat cells incubated with 10 µM of 
peptide 26 for 30 min (Fig. 3.2B). More studies are needed to identify the punctate 
pattern and the cellular uptake mechanisms of CFDA labeled peptides. We suspect that 
peptide 26 was taken up by Jurkat cells via a combination of direct permeabilization and 
endocytosis.  
We have also examined cytotoxicity of peptide 26 to Jurkat T cells. The cells 
were first incubated with 10 µM peptide 26 for 30 min, and then stained with cell vital 
dye trypan blue. Trypan blue is commonly used not only to assess cell viability, but also 
to quench extracellular fluorescence in flow cytometry analysis (Van Amersfoort and 
Van Strijp, 1994; Rejman et al., 2005). In our experiment, the dead cells would be stained 
with trypan blue and also lose fluorescence. As shown in Fig. 3.2C, the arrow is pointing 
to a dead cell, which has lost cell membrane integrity, thus stained by trypan blue and 
fluorescence quenched. However, most of the cells treated with peptide 26 for 30 min are 
viable and fluorescent. This result shows that when used at 10 µM, Fyn inhibitor peptide 
26 can readily penetrate Jurkat T cells, and doesn’t seem to be cytotoxic. However, in the 
later experiments, higher concentrations of peptide 26 were used to treat Jurkat cells. 
105 
 
Therefore, further studies are needed to determine cytotoxicity of peptide 26 when used 
at higher concentrations. 
 
 
      
 
Figure 3.2  Fluorescence microscopy imaging of peptide 26 uptake by Jurkat T cell.   
(A) Cellular uptake and accumulation of peptide 26 was observed as green fluorescence 
signal in live Jurkat T cells. Confocal images of a gradual increase of cellular 
fluorescence were captured every 1 min after adding peptide 26 to cells for 3 min. (B) 
Wide-field fluorescence image of Jurkat T cells incubated with 10 µM peptide 26 for 30 
min, then adhered on a poly-d-lysine coated plate. Fluorescein fluorescence is largely 
cytosolic, but a punctate pattern is observed. (C) 10 µM of peptide 26 was incubated with 
Jurkat cells for 30 min, then 0.2% trypan blue solution was added to stain for dead cells. 
The fluorescein fluorescence from the dead cells is quenched by trypan blue (arrow). 
A 
B C 
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Determination of IC50 and selectivity of cell permeable Fyn inhibitor.  After 
taken up by cells, peptide 26 is hydrolyzed to a fluorescein labeled peptide 27 (Scheme 
3.2). Compared to the lead compound 24 from the library, 27 not only contains two extra 
amino acids, but also a bulky negatively charged moiety close to the SH2 domain 
targeting component. Although we placed a spacer between the SH2 domain targeting 
sequence and the fluorophore, we suspect that these modifications are likely to alter the 
potency and selectivity of peptide 27 as a Fyn inhibitor. Therefore, we evaluated the IC50 
and the selectivity of peptide 27 (Table 3.2). As expected, the addition of extra amino 
acids and fluorescein had a negative influence on the potency and selectivity of the 
inhibitor. We have also tested the IC50 of peptide 25, which contains the Ahx and Lys 
amino acid spacer, but not labeled with fluorescein. With the extra amino acids only, the 
IC50 of peptide 25 for Fyn (IC50 = 0.046 µM) and Lck (IC50 = 10 µM) did not change 
much from the parent peptide 24 [Fyn (IC50 = 0.025 µM) and Lck (IC50 = 13.6 µM)]. In 
contrast, the fluorescein conjugated peptide 27 has a 0.41 µM IC50 for Fyn, and 65.3 µM 
IC50 for Lck, and the selectivity for Fyn over Lck is 159-fold. From these results, we 
decided that the cell permeable peptide exhibits good inhibitory behavior and high 
selectivity for Fyn, and therefore should serve as a good Fyn-selective inhibitor in 
subsequent cell based studies. 
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Table 3.2  IC50 and selectivity of peptide 24, 25 and 27 for Fyn and Lck. 
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Peptide 25 selectively pulls down Fyn over Lck from Jurkat cell lysate.  To 
see if the Fyn inhibitor peptide 25 is able to selectively bind to Fyn versus Lck in Jurkat T 
cell lysates, we performed an affinity pull-down assay. The affinity column was prepared 
by immobilizing peptide 25 on an Affigel resin through conjugation to the lysine side 
chain. Jurkat E6-1 cell lysate was added to the Affigel-peptide 25 affinity column. After 
incubation, the unbound proteins were collected from the flow through fraction, and the 
bound proteins were subsequently eluted by boiling the resins in SDS containing buffer. 
The relative amount of Fyn and Lck in cell lysate, flow through and elution was 
compared by Western blot using Fyn and Lck specific antibodies (Fig. 3.3). Denny et al. 
have previously determined that the relative levels of Fyn and Lck in Jurkat cells is 1:30 
(Denny et al., 2000). We found that, when used at the same dilution, the Lck antibody 
produces a much stronger signal than the Fyn antibody. Thus different dilutions for these 
two antibodies were used in the pull-down analysis to generate comparable 
chemiluminescence signals. Therefore, the Fyn and Lck signal strength shown in Fig. 3.3 
(INPUT) is not representative of the relative amount of Fyn and Lck expressed in Jurkat 
E6-1 cells.  
The pull-down assay demonstrated that the immobilized Fyn inhibitor 25 was able 
to selectively bind to Fyn over Lck in Jurkat cell lysate. However, we do note that not all 
Fyn protein has been pulled-down, and a small fraction of Lck also bound to the affinity 
column. We suspect this is because the Jurkat cells were lysed and used without TCR 
stimulation, thus Fyn and Lck kinases present in the cell lysate were not in the fully 
activated form. The bivalent inhibitor is designed to bind to the fully active Fyn kinase 
which exhibits an “open” conformation. When Fyn is in a “closed” inactive conformation, 
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the SH1 and SH2 domains are not positioned for the optimal binding by the bivalent 
inhibitor. Therefore, the selectivity of this peptide for inactive Fyn and Lck is likely to be 
moderate. 
 
 
 
 
Figure 3.3  Immobilized peptide 25 selectively pulls-down Fyn over Lck from Jurkat 
lysate. 
Jurkat E6-1 cell lysate was used for pull-down analysis by Affigel-peptide 25. The 
amount of Fyn and Lck from cell lysate (input), unbound fraction (flow through) and 
peptide bound fraction (elution) was analyzed by Western blot.  
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Effect of Fyn and Lck inhibitors on Pyk2 and LAT phosphorylation in 
stimulated Jurkat T cells.  Many studies have indicated that Fyn is able to selectively 
phosphorylate several protein substrates upon T cell stimulation, including Pyk2 (Qian et 
al., 1997), c-Cbl (Tsygankov et al., 1996; Feshchenko et al., 1998), Sam68 (Feuillet et al., 
2002), SKAP55 (Wu et al., 2002) and WASP (Badour et al., 2004). However, 
controversial data exists indicating that although not required, Lck may also play a role in 
phosphorylating some of these proteins. For example, knocking out Fyn doesn’t 
completely abolish Pyk2 phosphorylation (Collins et al., 2010b), and knocking down Lck 
causes a reduction in c-Cbl phosphorylation (Methi et al., 2008). 
Lck is generally believed to be the major contributor in proximal TCR signaling 
(Salmond et al., 2009), and has attracted more attention than Fyn. Proteins including 
ZAP-70 (Wang et al., 2010a), LAT (Jiang and Cheng, 2007), PLCγ1 (Lovatt et al., 2006), 
ezrin (Autero et al., 2003) and magicin (Lee et al., 2006) were shown to be selectively 
phosphorylated by Lck, although Fyn may also mediate LAT phosphorylation in the 
absence of Lck (Lovatt et al., 2006). In our study, considering the availability of 
phospho-specific antibodies, we choose to examine the phosphorylation of Pyk2 and 
LAT upon Jurkat TCR stimulation, and how the phosphorylation is affected by selective 
inhibition of Fyn or Lck.  
TCR stimulation induces rapid phosphorylation of Pyk2 on tyrosine residues 402 
and 580, and phosphorylation of LAT on tyrosine residue 191. As shown in Fig. 3.4A, 
stimulating Jurkat E6-1 cells with soluble anti-CD3 (OKT3) antibody induces fast 
phosphorylation of Pyk2 Tyr-580 and LAT Tyr-191. The maximum phosphorylation 
occurs between 1 - 2 min after stimulation for both sites. Previous studies have shown 
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that the Src family kinase inhibitor PP2 [Fyn (IC50 = 6 nM); Lck (IC50 = 5 nM)] is able to 
completely suppress Fyn and Lck activity in T cells (Collins et al., 2010b). To confirm 
this finding, we used another potent cell permeable Src kinase inhibitor AZD0530 [Fyn 
(IC50 < 10 nM); Lck (IC50 < 4 nM)] (Green et al., 2009). After pre-treating Jurkat cells 
with 10 µM AZD0530 for 10 min, no detectable Pyk2 and LAT tyrosine phosphorylation 
was observed in stimulated T cells (Fig. 3.4B). Therefore, our results confirm that TCR 
induced phosphorylation of Pyk2 and LAT requires Src family kinase activity. 
 
Figure 3.4  TCR induced Pyk2 and LAT phosphorylation requires Src family kinase 
activity.  
(A) Jurkat E6-1 cells were stimulated with 10 µg/mL anti-CD3 antibody (OKT3) for 0–
15 min. Phosphorylation of Pyk2 Tyr-580 and LAT Tyr-191 was examined by Western 
blot. (B) Phosphorylation of both proteins was abolished by pre-treating the cells with 10 
µM SFK inhibitor AZD0530 for 10 min.   
A 
B 
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The previous experiment demonstrated that phosphorylation of Pyk2 and LAT 
upon TCR stimulation requires Src family kinase activity. Therefore, we wanted to 
examine if Lck and Fyn play different roles in phosphorylating Pyk2 and LAT. Jurkat 
E6-1 cells were pre-treated with various doses of cell permeable kinase selective 
inhibitors, and then stimulated with anti-CD3 (OKT3) antibody for 1 min. The 
phosphorylation of Pyk2 Tyr-402 and LAT Tyr-191 was examined by Western blot. As 
shown in Fig. 3.5A and Fig. 3.6A, minimum phosphorylation of Pyk2 and LAT is 
observed prior to TCR stimulation, whereas 1 min incubation with OKT3 induces 
significant phosphorylation for both proteins. Treatment with Lck inhibitor damnacanthal 
[Lck (IC50 = 17 nM), ~20-fold selective for Lck versus Fyn) (Faltynek et al., 1995)] 
induces a concentration dependent LAT phosphorylation reduction, with a 50% 
suppression in 30 µM damnacanthal treated Jurkat cells. In contrast, for all the doses 
tested, damnacanthal does not significantly affect Pyk2 phosphorylation compared to a 
DMSO treated control (Fig. 3.5B). These data are consistent with previously reported 
results by Collins et al., indicating Pyk2 phosphorylation does not require Lck activity, 
whereas LAT Tyr-191 phosphorylation is dependent on Lck activation (Samelson, 2002; 
Collins et al., 2010b). 
To test if Pyk2 phosphorylation is dependent on Fyn activity, we pre-treated 
Jurkat cells for 10 min with an increasing concentrations of cell permeable Fyn selective 
inhibitor peptide 26 [the in cell hydrolyzed form 27 has a 0.41 µM IC50 for Fyn and 159-
fold selective for Fyn versus Lck] (Fig. 3.6). However, no significant change of Pyk2 
phosphorylation was observed for doses up to 30 µM. This result might indicate that Fyn 
kinase activity is not required for Pyk2 phosphorylation. However, we were surprised to 
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find that LAT phosphorylation is suppressed over 20% in 1 µM or 30 µM peptide 26 pre-
treated cells, but not in 5-20 µM dose range. With the current data in hand, we are not 
able to give an explanation for this observation. However, we suspect that during cell 
delivery, some peptides were trapped in the endosome-like structures. Therefore not 
enough peptide is present in the cytosol after 10 min incubation. In addition, it is also 
possible that peptide 26 (or the hydrolyzed 27) might have been degraded or 
dephosphorylated in cells. Indeed, rapid peptide degradation and dephosphorylation have 
been observed in living cells by CE analysis, as demonstrated in Chapter 2. 
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Figure 3.5  Effect of Lck inhibitor damnacanthal treatment on Pyk2 and LAT 
phosphorylation. 
(A) Western blot analysis of Pyk2 Tyr-402 and LAT Tyr-191 phosphorylation upon 
OKT3 stimulation in the absence or presence of increasing concentrations of cell 
permeable Lck selective inhibitor damnacanthal. (B) Densitometry analysis of Western 
blot results. The signal from pY402 Pyk2 and pY191 LAT was normalized to β-actin 
loading control. The normalized phosphorylation levels from inhibitor treated samples 
were compared to DMSO treated sample (0 µM). Data was averaged from at least 3 
independent experiments. Error bars are showing SEM.  
A 
B 
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Figure 3.6  Effect of cell permeable Fyn selective inhibitor 26 treatment on Pyk2 and 
LAT phosphorylation. 
(A) Western blot analysis of Pyk2 Tyr-402 and LAT Tyr-191 phosphorylation upon 
OKT3 stimulation in the absence or presence of increasing concentrations of cell 
permeable Fyn selective peptide inhibitor 26. (B) Densitometry analysis of Western blot 
results. The signal from pY402 Pyk2 and pY191 LAT was normalized to β-actin loading 
control. The normalized phosphorylation levels from inhibitor treated samples were 
compared to DMSO treated sample (0 µM). Data was averaged from at least 3 
independent experiments (except for 30 µM inhibitor treated pY191 LAT level, which is 
the average of two experiments). Error bars are showing SEM. * p=0.0105, ** p=0.0253 
A 
B 
116 
 
Conclusions 
We have discovered a potent and selective Fyn kinase inhibitor from screening a 
small library of photo-cleavable bivalent peptides. This inhibitor (peptide 24) exhibits a 
25 nM IC50 for Fyn and a ~550-fold selectivity against Lck. To utilize this inhibitor for 
cellular studies, we designed an uptake-and-report strategy by attaching a profluorescent 
CFDA moiety to the C-terminus of the inhibitor peptide, aiming to screen for novel cell 
delivery agents. We were surprised to find that the CFDA conjugated peptide 26 is 
permeable to Jurkat E6-1 cells. However, punctate endosome-like patterns were observed. 
Therefore, it would be useful to further study the uptake mechanism of CFDA labeled 
peptide, and also explore the application of this new cell delivery strategy to other 
peptide sequences and other cell types. 
Some studies showed that Pyk2 can be specifically phosphorylated by activated 
Fyn kinase (Qian et al., 1997), whereas other indicates that Lck may also play a role in 
Pyk2 phosphorylation (Collins et al., 2010b). We found that pretreating Jurkat E6-1 cells 
with various doses of Fyn inhibitor 26 or Lck inhibitor damnacanthal does not 
significantly affect Pyk2 phosphorylation. However, a potent Src family kinase inhibitor 
AZD0530 abolishes phosphorylation of both proteins. This might support the findings by 
Collins et al. that Lck is not required, but is sufficient to phosphorylate Pyk2 (Collins et 
al., 2010b). However, the phosphorylation of a T cell adaptor protein LAT is suppressed 
not only in a dose dependent manner by Lck inhibitor damnacanthal, but also by 
pretreatment of 1 µM or 30 µM of Fyn inhibitor. From these results, we can’t conclude 
that LAT phosphorylation requires both Fyn and Lck activity. However, we suspect that 
the observed effect of Fyn inhibitor on Pyk2 and LAT phosphorylation might be due to 
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different cytosol concentrations after 10 min pre-incubation, due to intracellular peptide 
degradation and/or dephosphorylation of the peptide. Therefore, further characterization 
of the cellular concentration as a function of incubation time and concentration, as well as 
the stability of the Fyn inhibitor inside living Jurkat cells, is essential in understanding 
the observed phenomenon, and to proceed with further investigations. 
 
  
 
CHAPTER IV 
CONSTRUCTION OF A PHOTOACTIVATABLE PROFLUORESCENT ENZYME 
VIA PROPINQUITY LABELING 
 
Elucidation of protein structure/function relationships has a long and storied 
history. However, for a wide variety of reasons, these relationships can be difficult to 
discern. For example, there is often a pronounced spatiotemporal component associated 
with protein action and the attendant biological consequences. In this regard, one 
particularly noteworthy protein is the cAMP-dependent protein kinase (PKA), which is 
associated with an array of organelles and supramolecular complexes, yet the 
ramifications of its action at these sites are distinct (Taskén and Aandahl, 2004).  
In recent years, one of the emerging areas of chemical biology is the use of photo-
sensitive molecules to study the signaling networks in cells (Priestman and Lawrence, 
2010), and cell behavior upon activation (or deactivation) of these light-responsive 
compounds (Ellis-Davies, 2007; Gorostiza and Isacoff, 2008). Among the photo-sensitive 
biological effectors, light-activatable (“caged”) proteins are a very interesting category 
and have attracted much attention. Caged proteins represent a potentially powerful means 
to address the relationship between protein activity and cellular behavior as a function of 
time and location (Lawrence, 2005; Mayer and Heckel, 2006; Lee et al., 2009; Priestman 
and Lawrence, 2010; Gautier et al., 2011). Caged proteins allow researchers to control 
protein activity by light irradiation at the cellular and tissue level. This provides a tool to 
allow the study of their biological functions in a spatial and temporal manner. Caged 
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biological effectors (including caged proteins) can be introduced into a biological system 
and subsequently turned-on by a UV lamp (global uncaging, appropriate for a large cell 
population) (Lee et al., 2011), or by a focused laser beam under the microscope (local 
uncaging, appropriate for single cells or subcellular studies) (Ghosh et al., 2004).  
Protein caging has been achieved in several ways: (a) chemical modification of 
existing critical nucleophilic residues with photo-cleavable moieties (Marriott, 1994; 
Golan et al., 1996; Marriott and Heidecker, 1996; Priestman et al., 2011), (b) site-directed 
mutagenesis-mediated insertion or deletion of reactive residues (Chang et al., 1995, 1998; 
Ghosh et al., 2004), (c) enzyme-directed insertion of reactive functionality (Zou et al., 
2002), (d) unnatural amino acid mutagenesis-mediated introduction of caged amino acids 
(Wang et al., 2006a; Lee et al., 2009; Riggsbee and Deiters, 2010), (e) semisynthetic 
proteins generated by expressed protein ligation (Hahn and Muir, 2004; Pellois et al., 
2004; Hahn et al., 2007), (f) using caged small molecule effectors or light-deactivatable 
inhibitors (Kawakami et al., 2008; Li et al., 2008a; Georgianna et al., 2010; Karginov et 
al., 2010; Riggsbee and Deiters, 2010; Priestman et al., 2011), and (g) genetically 
encoded incorporation of light-responsive proteins (Lee et al., 2008a; Strickland et al., 
2008; Levskaya et al., 2009; Wu et al., 2009; Kennedy et al., 2010). 
The cAMP-dependent protein kinase (PKA) plays important roles in several 
signaling pathways, and is one of the most studied protein kinases. The PKA holoenzyme 
consists of two catalytic domains and two regulatory domains. The catalytic subunit has 
been used to develop the caged derivatives. There are three reactive residues on PKA 
catalytic subunit, Cys-199, Cys-343 and Thr-197. Cys-199 and Thr-197 are in the 
activation loop, and are critical for the enzymatic activity. Bayley et al. covalently 
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modified Cys-199 with nitrobenzyl caging groups and reported 5% residual activity and 
up to 30-fold activity recovery after photolysis (Chang et al., 1998). Thr-197 has also 
been modified by first inserting a reactive thiophosphate via an enzyme-directed reaction, 
then caging the phosphate group with a photo-cleavable moiety. This strategy resulted in 
6% residual activity and up to 90% activity recovery after photolysis (Zou et al., 2002). 
PKA Cys-199 has also been selectively modified via an active-site directed peptide, 
which was designed to promote a weak active-site binding and thus induce an affinity 
labeling of Cys-199. This design successfully reduced PKA activity to less than 2%, and 
photolysis induced a 25-fold activity enhancement (Curley and Lawrence, 1998).  
In addition to controlling protein activity by light, it would also be useful if the 
uncaging and location of the modified species could be observed. When researchers use 
caged molecules to decipher the complex intracellular pathways, the only feedback from 
the experiment is the biological response that is directly or indirectly generated from the 
photo-activated effectors. However, if no desired biological response is observed, it can 
be extremely difficult to decide if this is due to unsuccessful uncaging or some other 
unexpected mechanism. Therefore, a strategy that allows visual evaluation of the extent 
of photo-uncaging, and, the location and movement of the photo-activated effectors in 
real time is desirable. There are two different approaches to generate the uncage-and-
report system. One is to use a profluorescent caging group. This type of caging group, 
after photolysis, is transformed into an active fluorophore, hence the extent of photolysis 
can be visually evaluated fluorescently. Kutateladze and co-workers have developed a 
thioxanthone-based system that furnishes an up to 17-fold enhancement in response to 
photo-cleavage (Majjigapu et al., 2005). Another uncage-and-report strategy is to use a 
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fluorophore tethered to a quencher via a photolabile linker. Compared to the small 
profluorescent caging groups, this design has the advantage of being used for real-time 
tracking if the fluorophore, after photolysis, remains on the activated protein.  Muir and 
co-workers prepared a caged protein construct (Smad2) via expressed protein ligation 
using a fluorescein-photolabile linker-dabcyl cassette and reported a 26-fold fluorescence 
enhancement upon photo-activation in the test tube (Pellois et al., 2004). 
In this project, we have successfully developed a new uncage-and-report system 
that utilizes peptide-based active site recognition and affinity labeling strategy (Yan et al., 
1996; Curley and Lawrence, 1998; Harvey and Trauner, 2008) to modify a non-active 
site residue in PKA catalytic subunit, and prepared a caged profluorescent PKA (Fig. 4.1).  
 
 
 
Figure 4.1  The uncage-and-report design of a caged profluorescent PKA. 
  
Inactive PKA 
Low fluorescence 
Active PKA 
Bright fluorescence 
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Materials and Methods 
Peptide synthesis.  All amino acids, Fmoc-PEG-linker, NovaSyn TGR resin, 
HCTU were obtained from NovaBiochem. 4-{4-[1-(9-fluorenylmethyloxycarbonylamino) 
ethyl]-2-methoxy-5-nitrophenoxy}butanoic acid (Fmoc-photolabile linker) was 
purchased from Advanced ChemTech. DMF, DCM, and other general solvents were 
purchased from Fisher Scientific. DIPEA was purchased from Sigma. 5-
carboxyltetramethylrhodamine (5-TAMRA) was purchased from ChemPep. QSY7-
maleimide was purchased from Invitrogen. N-succinimidyl 6-maleimidohexanoate was 
purchased from TCI America. 
Ac-G-R(pbf)-T(tBu)-G-R(pbf)-R(pbf)-N(OtBu)-A-I-H(trt)-D(OtBu)-PEG-C(trt)-
photolinker-K(ivDde)-K(Boc)-CONH2 was synthesized on the TGR resin (0.2 mmol/g, 
500 mg resin, 0.1 mmol scale). A standard peptide coupling protocol was used for all 
amino acid couplings including the Fmoc-photolabile linker. Amino acid (5 equiv/equiv 
resin), HCTU (5 equiv/equiv resin) and DIPEA (12 equiv/equiv resin) were mixed with 
resin in DMF and reacted for 10 min at room temperature using a Protein Technology 
International Prelude peptide synthesizer. Fmoc deprotection was achieved using 20% 
piperidine in DMF for 20 min at RT. The N-terminus was capped using acetic anhydride 
with 20% DIPEA for 20 min. 
The dye labeling procedure was performed by Dr. Hsien-ming Lee. Briefly, after 
Lys side chain (ivDde) was deprotected and labeled with TAMRA, the peptide was 
cleaved from the resin and purified by HPLC. The purified TAMRA labeled peptide was 
then reacted with QSY7-maleimide quencher to generate the fluorescence quenched 
peptide.  
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Preparation of caging agent 28-PKA catalytic subunit conjugate.  The caging 
agent 28 was prepared by Dr. Hsien-ming Lee. Briefly, the fluorescently quenched 
peptide was HPLC purified and then reacted with N-succinimidyl 6-maleimidohexanoate 
to install the maleimide functional group at the lysine side chain. The reaction mixture 
was then HPLC purified to obtain the caging agent 28. 
20 µM mouse c-AMP dependent protein kinase (PKA) catalytic subunit α 
(purchased from Promega: V5161, or expressed and purified by Dr. Hsien-ming Lee) was 
dialyzed against the “reaction buffer” (100 mM Tris buffer with 10% glycerol, 100 mM 
KCl at pH 7.5) at 4 ˚C overnight. Two reaction solutions were prepared: (1) PKA 
solution: 5 μL of 200 mM ATP and 200 mM MgCl2 mixture stock solution was added to 
reaction buffer containing PKA (100 μL, 20 μM, 2.0 nmol) to furnish a solution that 
contained 9.5 mM ATP and 9.5 mM MgCl2. (2) Caging agent solution: 2.2 eq of caging 
agent 28 (5 mM, 4.4 nmol, 0.8 μL) stock in DMSO was diluted using the reaction buffer 
containing 10 mM ATP and 10 mM MgCl2 to make a 15 μL caging agent (266 μM) 
solution. The caging agent solution was slowly added into the PKA solution and the 
resulting mixture was incubated at 4 °C for 12 h. The resultant caged PKA was dialyzed 
against PBS containing 100 μM DTT overnight for buffer exchange, and then stored at 
4 °C. Prionex was added (to 1% final concentration) to caged PKA destined for 
intracellular microinjection to prevent aggregation that might clog the microinjection 
needle. Purchased (from Sigma Aldrich) Prionex solution 10% (w/v) was dialyzed 
against 100 mM Tris buffer with 100 mM KCl prior to use. 
SDS-PAGE analysis of caged PKA.  As a consequence of the significant 
molecular weight associated with the caging agent 28 (3680 g/mol), the SDS-PAGE 
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technique provides a mean to assess the extent of PKA labeling. NuPAGE 4 - 12% Bis-
Tris precast gel from Invitrogen was chosen for this purpose due to its high resolution 
performance. Molecular weight marker and samples (5 µL of each protein solution was 
mixed with 5 µL of 4X loading buffer, water was added up to a volume of 20 µL) were 
gel loaded. Samples were loaded without heating. The gel was run at 200 V for 40 min. 
The gel was stained using Bio-Safe Coomassie and pictures obtained using the FluoChem 
system.  
Labeling yield (i.e. yield of caged PKA) was estimated using SDS-PAGE analysis. 
In brief, the band corresponding to caged PKA was compared to that of unmodified PKA. 
Quantification of the bands furnishes an estimation of labeling yield for the desired caged 
PKA conjugate. 
PKA catalytic activity measurement.  PKA activity was measured as previously 
described (Cook et al., 1982). In brief, the assay couples the formation of ADP to the 
generation of pyruvate (catalyzed by pyruvate kinase), which is in turn reduced to lactate 
via the NADH-dependent lactate dehydrogenase. 198 μL of the assay solution containing 
50 mM Tris pH 7.5, 100 mM NaCl, 10% glycerol, 10 mM MgCl2, 1 mM ATP, 1 mM 
DTT, 1 mM Leu-Arg-Arg-Ala-Ser-Leu-Gly (kemptide), 1 mM phosphoenolpyruvate, 0.2 
mM NADH (Sigma) and 1X coupling enzymes (lactic dehydrogenase and pyruvate 
kinase) was added into a 200 μL quartz cell and the NADH absorbance over time at 340 
nm was measured for 1 min as the background. 2 μL of PKA solution with unknown 
activity was then added into the assay mixture and the NADH absorbance decrease over 
time was measured. The slope of the absorbance decrease, after subtracting the 
background slope, directly reflects the activity of the kinase being measured. 
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Kinase activity as a function of irradiation time.  20 μL of 15 μM caged PKA 
was diluted to 60 μL (5 μM PKA) using the uncaging solution (100 mM Tris pH 7.5, 100 
mM KCl, 10 mM DTT with 1% Prionex as a protein stabilizer, with freshly added DTT). 
The caged PKA in the uncaging solution was placed in an ice water bath and irradiated 
using a Hg Arc lamp in the presence of a color glass filter UG-1 (250 mW/cm2) for 
different time periods (from 5 to 180 s). For every time point, 5 μL of irradiated PKA 
solution was aliquoted. Activity measurements were obtained using a coupled assay 
(Cook et al., 1982) for each time point. The activity of non-irradiated PKA was also 
measured. Specific activity was calculated as the slope of the change in absorbance/time 
divided by the PKA concentration. The specific activity of uncaged PKA is reported as a 
percentage of the specific activity of wild type PKA.  
Mass spectrometry characterization.  Both the wild type catalytic subunit of 
PKA and its caged counterpart were subjected to in-gel trypsin digestion prior to mass 
spectral analysis (MALDI-TOF and MS/MS was performed by the Proteomic core 
facility in University of North Carolina at Chapel Hill). In brief, the gel pieces were 
destained via treatment with a 1:1 mixture of CH3CN:50 mM NH4HCO3 by shaking in a 
thermomixer for 10 min at 25 °C and removing the solution (3x). The gel was then 
“dehydrated” via three washings with pure CH3CN (10 min at 25 °C in thermomixer) and 
then dried. The gel was then exposed to trypsin on ice for 20 min and the solution drained. 
The gel was subsequently incubated with 25 mM NH4HCO3 in a thermomixer at 36 °C 
overnight. CH3CN was added to the solution, shaken for 10 min at RT and the combined 
solution transferred to an Axygen tube.  
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Inhibition of active site-directed caging of PKA.  An assessment of whether the 
labeling of PKA is driven by active site recognition of the caging agent was performed by 
conducting the labeling reaction with caging agent 28 in the absence and presence of 
“PKI 5-24”, an active site-targeted reversible inhibitor (purchased from Sigma-Aldrich). 
The reaction was performed as described above in the Preparation of caging agent 28-
PKA catalytic subunit conjugate section except that the reaction time was 4 h (instead 
of 12 h). The reactions in the presence or absence of PKI 5-24 fragment were carried out 
simultaneously. Absence of PKI 5-24: sequentially mix 22.2 μL PKA solution, 22 μL 
H2O and 1.66 μL caging agent 28. Presence of PKI 5-24: sequentially mix 22.2 μL PKA 
solution, 22 μL PKI 5-24 (1 mM, 22 nmol, 100 eq) and 1.66 μL caging agent 28. The 
resulting mixtures were incubated at 4 °C for 4 h. After 4 h, 22 μL of the reaction 
mixtures were taken out from each tube, and 0.25 μL of 100 mM DTT was added to stop 
the reaction. Then 8 μL 4X NuPAGE loading buffer was added to the mixtures, and the 
solutions (30.25 μL) were gel loaded. 
 Cell culture.  REF52 cells (provided by Professor Rudy Juliano at UNC-CH) 
were grown in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal calf 
serum (FCS) and 1% P/S at 37 °C in a 5% CO2 incubator. 24 h prior to the microscopy 
experiments, 2-3 X 104 cells were seeded onto fibronectin-coated glass bottom plates in 
10% FCS containing Leibovitz’s L-15 medium. MatTek 50 mm gridded glass bottom 
dishes were used for experiments requiring microinjection or photolysis. MatTek 6-well 
glass bottom plates were used for experiment with cell permeable reagents. 
Fibronectin glass bottom plate coating was achieved by incubating 5 µg/mL 
fibronectin (BD Biosciences) with the glass bottom plates for 1 h at 37 °C in a 5% CO2 
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incubator. After removing the fibronectin containing buffer, the plates were let dry in a 
cell culture hood overnight. 
Fluorescence microscopy.  All fluorescence imaging experiments were 
performed using an inverted Olympus IX81 microscope with a Hamamatsu C8484 
camera and FITC, Cy3 and Cy5.5 filter cubes (Semrock). Microinjection was performed 
using an Eppendorf FemtoJet and Injectman NI 2 system. Photolysis experiments were 
performed by centering the cell culture dish under an Oriel Hg arc lamp system (NewPort, 
power supply model 69907, 200 W Hg Arc lamp). A 360 nm color glass filter (300-400 
nm band pass, NewPort, model UG-1) was placed on top of the cell plate cover. All 
imaging analyses were performed using Metamorph software. 
CPT-cAMP induced stress fiber disappearance.  REF52 cells were seeded on 
fibronectin-coated wells for 24 h prior to experiments using 6-well plates. Cells were 
incubated with CPT-cAMP (500 μM) in 10% FCS L-15 medium for 30 min, washed with 
PBS, permeabilized with 0.1% Triton X-100/PBS for 10 min at RT, and stained with 
Alexa Fluor 488 phalloidin (Invitrogen) in 1% BSA containing PBS buffer for 20 min at 
room temperature. Fluorescent images of phalloidin-labeled actin were taken at 100 ms 
exposures using a FITC filter cube.  
Photolysis-induced change in fluorescence of REF52 cells microinjected with 
caged PKA.  20 μM caged PKA catalytic subunit with 10 μM dextran Alexa 680 in the 
microinjection needle (Femtotips II, Eppendorf) was microinjected (injection pressure 
100 hPa, injection time 2 s, compensation pressure 20 hPa) into REF52 cells. Cells were 
subsequently washed with 2 mL of 10% FCS containing L-15 medium. Images were 
acquired using 500 ms exposure with the Cy3 filter cube (TAMRA), furnishing initial 
128 
 
fluorescence prior to photolysis. The sample was illuminated (360 nm filter) under an Hg 
Arc lamp for 5 min. Following photolysis, the cells were allowed to recover at 37 °C for 
1 h (5% CO2 incubator) and subsequently fixed (4% paraformaldehyde/PBS for 10 min). 
Images of TAMRA fluorescence were then reacquired as described above. The 
fluorescence change upon photolysis was obtained by subtracting both the initial cell 
fluorescence and the photobleaching from the acquired fluorescence for each 
microinjected cell. 
Photolysis-induced loss of stress fibers in REF52 cells microinjected with 
caged PKA.  Following the acquisition of TAMRA fluorescence as described in the 
previous paragraph, the fixed cells were permeabilized in 0.1% Triton X-100/PBS (10 
min), and stained with Alexa Fluor 488 phalloidin (Invitrogen) in 1% BSA/PBS (20 min). 
Fluorescent images of phalloidin-labeled actin were taken using a 100 ms exposure time 
with a FITC filter cube. 
TAMRA photobleaching.  Free TAMRA (50 μM in microinjection needle; 
injection conditions as described above with caged PKA) were microinjected into REF52 
cells to measure the fluorescence decrease during photolysis and imaging. Following 
microinjection, the cells were washed, imaged and photolyzed in a fashion identical to 
that described with caged PKA. However, since free TAMRA is not fixed by 
paraformaldehyde, the fluorescence images of TAMRA after photolysis were performed 
without fixation.  
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Results and Discussion 
Design and synthesis of the caging agent 28.  The catalytic subunit (C) of PKA 
contains two readily modifiable Cys residues, one at the base of the active site (Cys-199) 
and the other approximately 20 Å removed (Cys-343) (Fig. 4.2A). Covalent modification 
of Cys-199 destroys catalytic activity and thus represents a poor choice for tagging the 
enzyme with a fluorophore label (Mobashery et al., 1990; Salerno and Lawrence, 1993; 
Yan et al., 1996; Chang et al., 1998; Curley and Lawrence, 1998). Consequently, we 
focused our attention on the non-active site Cys-343 moiety for this purpose. The C 
subunit catalyzes the phosphorylation of Ser and Thr residues ensconced within targeted 
sequences (-Arg-Arg-Xaa-Ser-) of protein and peptide substrates (Pinna and Ruzzene, 
1996). In addition, peptide-based inhibitors have been constructed by replacing the 
phosphorylatable Ser moiety with a nonphosphorylatable Ala residue (Dalton and Dewey, 
2006). The caging agent 28 contains a (i) validated active site-directed inhibitory peptide 
sequence, GRTGRRNAIHD (“PKI”) (Dalton and Dewey, 2006), (ii) a polyethylene 
glycol (PEG) spacer to optimally position an appended electrophilic maleimide near Cys-
343, and (iii) a tripeptide cassette composed of a photolabile (PL) moiety inserted 
between a fluorophore and a fluorescent quencher. The cassette employed in this study 
[Cys(QSY7)-PL-Lys(TAMRA)], shown explicitly in the caging agent 28 (Fig. 4.3) and 
schematically in Figs 4.2B and 4.2C, was derived from a library of fluorescently 
quenched cassettes (Lee et al., 2010a). The latter were screened to identify an 
arrangement of fluorophore, quencher, and photolabile moiety that optimizes the 
fluorescent response upon photo-cleavage. Consequently, photolysis of the covalently 
modified, and therefore inactive, protein kinase (Fig. 4.2C), is designed to both restore 
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enzymatic activity and simultaneously generate a fluorescent protein via release of the 
active site-directed PKI fragment and the appended quencher moiety (Fig. 4.2D). 
 
Figure 4.2  Design of the caged profluorescent PKA.  
(A) Native PKA C subunit highlighting the active site Cys-199 and its non-active site 
Cys-343 counterpart. (B) Active site-directed alignment of the maleimide (E) of the 
caging agent near Cys-343. (C) Caged profluorescent PKA C subunit. (D) Photolyzed C 
subunit, with fluorophore remains on the protein. Q = Quencher; F = Fluorophore; = 
PL (photolabile linker). 
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Figure 4.3  Structure of the caging agent 28.  
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 Preparation of caged PKA catalytic subunit.  The caged enzyme (<3% 
residual activity) was acquired by exposing the native PKA C subunit to caging agent 28 
(details are described in Preparation of caging agent 28-PKA catalytic subunit 
conjugate section). To demonstrate that the labeling reaction is indeed driven by protein-
ligand recognition, we compared the modification efficiency of the caging agent 28 to 
PKA in the presence or absence of the active site-directed reversible inhibitor PKI 5-24. 
As shown in Fig. 4.4, 25% of caged PKA was formed in the absence of reversible 
inhibitor, whereas the presence of reversible inhibitor competitively prohibited 
modification of PKA with the caging agent. 
 
      Lane 1                   Lane 2                   Lane 3 
 
Figure 4.4  Caging agent 28 labeling PKA reaction is driven by protein-ligand 
recognition.  
SDS-PAGE of wild type C subunit of PKA (lane 1), C subunit treated with the caging 
agent 28 (lane 2), and C subunit treated with the caging agent 28 in the presence of the 
active site-directed reversible inhibitor PKI 5-24 (lane 3) for 4 h. The densities of the 
bands were analyzed using ImageJ. In the absence of reversible inhibitor: caged PKA is 
25% and unmodified PKA is 75%. In the presence of reversible inhibitor: caged PKA is 
9.6% and unmodified PKA is 90.4%. 
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Mass spectrometry characterization of caged PKA.  Mass spectrometric 
comparison of the wild type PKA and caged PKA revealed a series of unique masses for 
the latter. Specifically, trypsin-treated caged PKA displays a distinctive mass of 3259.45, 
which corresponds to a Cys-Gly-Lys containing fragment 29, a fragment that can only be 
derived from the Cys343 sequence (-Asn340-Glu-Lys-Cys-Gly-Lys-Glu-Phe-Thr-Glu-
Phe350) (Fig. 4.5A). In addition, mass spectrometric analysis of trypsinized photolyzed 
caged PKA revealed a distinctive mass of 1434.1, which corresponds to the fragment 30, 
a fragment also can only be derived from the Cys343 sequence (Fig. 4.5B). Because 
photolysis was performed in the presence of dithiotheitol, which can convert photo-
cleavage byproduct arylnitroso derivatives into arylamines (Dölle et al., 1980), therefore, 
fragment 30 contains an arylamine, and not the initially formed arylnitroso.  
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Figure 4.5  Mass spectrometry characterization of caged PKA.  
(A) 3138 – 3519 m/z region of trypsin-treated (a) wild type PKA and (b) caged PKA. 
Highlighted peak (red arrow) corresponds to Cys343-modified fragment 29. 
(B) 1393 - 1456 m/z region of trypsin-treated photolyzed caged PKA. Highlighted peak 
(black arrow) corresponds to Cys343-modified fragment 30. 
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Photolyzation of caged PKA in live cells.  Stress fibers are bundles of actin that 
interface with focal adhesions and thereby link the cytoskeleton of the cell with the 
extracellular matrix. cAMP, as well as active PKA, drives the disassembly of stress fibers 
along with attendant morphological changes, and therefore serves as a good biological 
readout for PKA activation (Lamb et al., 1988; Roger et al., 1988; McNamee et al., 1995). 
The effect of active PKA on stress fiber disassembly is mediated via several pathways, 
including suppression of collagen-induced actin polymerization (in endothelial cells) 
(Whelan and Senger, 2003), phosphorylation and inhibition of Rho function, which is 
important for stress fiber formation (Kreisberg et al., 1997), and stimulation of the SHP2 
(SH2-domain containing phosphotyrosine phosphatase) phosphatase activity, which 
negatively regulates Rho function and stress fiber integrity (Alan K, 2004). 
We decided to examine the ability of caged PKA to promote stress fiber 
disassembly in a light-dependent fashion. We choose rat embryo fibroblasts (REF52) for 
our study because of its flattened cell shape and well organized actin stress fibers. We 
first treated REF52 cells with a cell-permeable form of cAMP (CPT-cAMP), and, as 
expected, we observed complete or partial loss of actin stress fibers in most cells. The 
cells also rounded up and left long processes, displaying a characteristic cAMP induced 
stellate morphology (Fig. 4.6) (Dong et al., 1998). Similar morphological changes were 
also observed in cells microinjected with wild-type PKA C subunit (Fig. 4.7).  
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Figure 4.6  Actin staining of untreated and CPT-cAMP-treated REF52 cells.  
(A, B) REF52 cells seeded on fibronectin coated plate with 10% FCS in L-15 media are 
flat and tightly adherent, and contain stress fibers. (C, D) Treating cells with 500 μM 
CPT-cAMP in L-15 media containing 10% FCS for 30 min induces either partial or 
complete lost of stress fibers. The cells also round up and leave long processes, which is 
the characteristic stellate morphology induced by increased intracellular cAMP level. [(A) 
and (C) are transmitted light images; (B) and (D) are fluorescence images taken using a 
FITC filter cube.] 
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Figure 4.7  Morphology change in wtPKA injected REF52 cell.  
(A) Fluorescence image (FITC filter cube) of 10 µM wtPKA microinjected (arrow) and 
non-microinjected cells fixed, permeabilized and stained with phaollidin-Alexa 488. (B) 
Fluorescence image (Cy5.5 filter cube) of microinjected cell (arrow) showing 
microinjection marker dextran-Alexa 680 fluorescence. Images were taken after 1 h 
incubation post-microinjection and subsequent fixation. Both images are of the same field. 
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After demonstrating that active PKA can induce stress fiber loss and cell shape 
change, we examined whether the same cell behavior is induced by light using caged 
PKA, and at the same time observe fluorescence enhancement. To exclude the possibility 
that microinjection and/or light illumination might perturb cell signaling and induce 
unwanted cell behavior, we first examined if these two treatments have any effect on cell 
morphology. As shown in Fig. 4.8, photolysis alone does not affect REF52 cell 
morphology and stress fiber integrity. In addition, microinjection of REF52 cells with 
caged PKA, in the absence of subsequent photolysis, also has no effect on cell shape and 
stress fibers. Moreover, in microinjected cells, the dim TAMRA fluorescence from the 
caged PKA is reduced, possibly due to photobleaching during image captures. (Fig. 4.9).  
 
Figure 4.8  Stress fibers in photolyzed non-microinjected cells were retained. 
(A) Transmitted light image of photolyzed REF52 cells. (B) REF52 cells were 
photolyzed for 5 min under a Hg Arc lamp, incubated for 1 h post-photolyzation and then 
fixed, permeabilized and stained with phaollidin-Alexa 488. Both images are of the same 
field.  
A B 
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Figure 4.9  Microinjected REF52 cells in the absence of illumination.  
(A) Transmitted light image of caged PKA microinjected (arrows) and non-microinjected 
cells incubated for 1 h after microinjection and then fixed. (B) Stress fibers in 
microinjected (arrows) and non-microinjected cells are retained. (C) and (D) TAMRA 
fluorescence intensity from the injected cells decreased 1.42-fold after fixation (without 
subtracting TAMRA photobleaching). [(C) Image taken immediately after microinjection; 
(D) image taken after 1 h incubation post-microinjection and subsequent fixation.] All 
images are of the same field. 
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In contrast, as shown in Fig. 4.10, cells microinjected with caged PKA, which 
were subsequently photolyzed for 5 min under a Hg Arc lamp, lost stress fibers. The 
morphological change from flat to round shape and the long processes are also apparent. 
At the same time, we observe a 6.2 ± 2.1-fold (after subtracting TAMRA photobleaching 
control shown in Fig. 4.11) enhancement in TAMRA fluorescence after photolysis. The 
fluorescence intensity appears strongest in the nuclear region of the cells. This is because 
the PKA construct is freely diffusible, and therefore associated TAMRA fluorescence is 
strongest in the region (nuclear) where the cell has the thickest path length. 
 
 
Figure 4.10  Photolysis of caged PKA induced stress fiber disappearance and 
fluorescence increase.  
A B
C D 
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(A) Transmitted light image of caged PKA microinjected (arrows) and non-microinjected 
cells incubated for 1 h after photolyzation and then fixed. (B) Only microinjected cells 
(arrows) display stress fiber loss and morphological changes upon global illumination of 
all cells. (C) and (D) TAMRA fluorescence intensity increases 6.2 ± 2.1 fold (after 
subtracting TAMRA photobleaching) upon photolyzation. [(C) Image taken immediately 
after microinjection; (D) image taken after 1 h incubation post-microinjection and 
subsequent fixation.] All images are of the same field. 
 
 
  
Figure 4.11  TAMRA fluorescence prior to and after photolysis.  
The fluorescence intensity of TAMRA prior to (A) and after (B) photolysis was 
quantified and used as a photobleaching control. A 1.39 ± 0.33 fold fluorescence intensity 
decrease was observed (averaged from 31 cells). All images are of the same field. 
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Conclusions 
Using the active site-directed peptide-based affinity labeling strategy, we have 
designed and developed a profluorescent caged PKA catalytic subunit. We have 
confirmed by activity measurement, protein gel analysis and mass spectrometry that the 
non-active site Cys-343 residue is modified. The caged PKA displays less than 3% 
residual activity, and photolysis results in up to 80% activity recovery and 20-fold 
fluorescence enhancement in the test tube. We have also successfully applied the caged 
PKA in living REF52 cells and observe a light-dependent loss of stress fiber integrity and 
the stellate morphology that is characteristic of elevated cAMP and PKA activity. 
Moreover, photolysis also induces a 6.2-fold TAMRA fluorescence enhancement in 
REF52 cells microinjected with caged PKA. 
We do note that many, but not all protein kinases possess a non-active site Cys 
residue positioned at the Cys-343 site in PKA. However, any modifiable Cys moiety that 
lies outside, but within the vicinity of, the active site could potentially serve as a covalent 
anchoring residue. Alternatively, it is relatively straightforward to incorporate a reactive 
Cys at an appropriate position via site-directed mutagenesis. In addition, although 
microinjection is a common biological tool, only a relatively small number of cells (~100) 
can be treated in this fashion at any given time. By contrast, cell permeable reagents offer 
a more robust strategy applicable to large cell populations. Therefore, cell permeable 
analogs of caging agent 28, could prove useful in this regard, since they can potentially 
modify the target protein in situ.  
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